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Foreword 
 
Although, in recent years, advances in diagnosis and treatment have been made, breast cancer remains a 
major public health issue in Ireland and is responsible for approximately 650 deaths annually. 
 
It is now recognised that patients with breast diseases are best served by a team of specialists working 
together.  Strong evidence exists that women with breast cancer are at lower risk of relapse and have a better 
opportunity of long-term survival if they are treated in a multidisciplinary setting.  Thus, surgeons, 
radiologists, pathologists, medical oncologists, radiotherapists, plastic surgeons, nurses, counsellors and 
others all bring expertise together to provide the best care for each patient.  Such an arrangement can be 
achieved only by establishing Specialist Breast Units, strategically placed throughout the country, each 
treating sufficiently large numbers of patients in order to maintain expertise and to promote best practice.  
These Units should also be responsive to developments in treatment and should be involved in clinical 
research and clinical trials in collaboration with each other and with international groups. 
 
Systems of training of breast specialists and guidelines of good care are being laid down by training 
organisations in Ireland and throughout Europe. 
 
The undoubted high quality of the recently initiated National Breast Screening Programme (Breast Check) 
for women aged 50-64 years who have no breast symptoms, should be matched by a programme also of the 
highest quality for women who have breast complaints. 
 
In April 1999, the Minister of Health and Children asked the National Cancer Forum to report and make 
recommendations on the development of breast services for symptomatic women.  The Forum established a 
subgroup to undertake this exercise, under the Chairmanship of Prof J. Fennelly. 
 
The report has now been approved by the Forum.  It is with great pleasure that I acknowledge the efforts of 
my colleagues on the subgroup in preparing this report.  It is also a pleasure to pass the report on to the 
Minister for Health and Children for consideration and, it is hoped, for implementation. 
 
 
Niall O’Higgins        March, 2000 
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Summary 
 
This is a detailed report.  To assist readers in extracting the key information without reading through the full 
report, the summary has been formulated so that it can stand alone.  In order to do this, it has been necessary 
to repeat some whole sections of the main report in the summary. 
 
Background 
 
Most women with breast symptoms fear that they may have cancer.  In the great majority of cases, the 
breast complaint is not due to cancer.  Nonetheless the anxiety generated by the possibility of this fearful 
diagnosis requires that women with breast symptoms are cared for in an efficient, sympathetic environment 
by highly trained specialist with access to high quality facilities.  These prerequisites are needed in order to 
provide a firm diagnosis of a benign or innocent condition without delay and thus be in a position to 
reassure the patient.  Equally, when the patient has cancer of the breast, the diagnosis and treatment must be 
carried out in a systematic fashion and in conformity with the high standards of care expected in a modern 
society. 
 
Breast cancer causes approximately 650 deaths in women each year in Ireland and thus presents a major 
public health issue.  It is the commonest fatal cancer in women.  While it is rare in women under the age of 
thirty years, it can affect all age groups and is responsible for a high proportion of premature deaths.  
Despite being the subject of intensive research, causes of breast cancer are still unknown.  It is recognised 
that, in general, the earlier the diagnosis of breast cancer is made, the more likely it is that patients will have 
a favourable outlook. Although by no means infallible, high quality mammography can lead to the 
identification of breast cancers when they are very small and when the prospect of cure after treatment is 
very high.  It is for this reason that screening programmes have been established.  Breast screening means 
the investigation of women who have no breast symptoms and who believe that they have no breast disease.  
The National Breast Screening Programme (NBSP), which commenced in January 2000, is a system where 
excellence is required in the identification and treatment of small cancers in women without breast 
symptoms.  The purpose of this screening programme is to reduce mortality from breast cancer in women in 
the fifty to sixty-four year age group. 
 
Because the screening programme will deal only with women in the fifty to sixty-four year old age range 
and only with those who have no symptoms, the great majority of women with breast cancer will continue 
to be diagnosed and treated outside of the screening programme.  For this reason, and because of the need to 
investigate and treat the large and increasing number of people with breast symptoms due to benign 
conditions, it is necessary to ensure that the attention and care provided for these patients is as good as that 
offered in the screening programme.  It is, therefore, essential to put systems in place to achieve this 
ambition. 
 
Genesis of the report 
 
A number of developments have led to the production of this report: 
• There is good evidence that outcomes for women with breast cancer are influenced by the method of 
care provided and that the use of clinical guidelines can improve the process and outcome of care. 
• Evidence demonstrating correlation between workload (volume) and survival exists.  In some cases, a 
20% improved survival has been noted in patients treated in specialised Breast Units compared to those 
not treated in such centres. 
• Throughout the UK, the USA and Europe there has been a demand for protocols in oncology especially 
for common cancers and guidelines are being formulated in the area of breast diseases. 
• Professional groups such as the Royal Colleges recognise that there is a relationship between longterm 
survival and the number of patients treated in particular centres and have advocated the establishment of 
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guidelines for the training o surgeons, radiologist, physicians and radiotherapists involved in breast 
disease. 
• Best practice guidelines have been widely promulgated and continuing medical education (CME) 
although voluntary at present is likely to become compulsory in the future for all doctors treating 
patients with breast cancer. 
• Establishment of agreed proformas and protocols of management consistent with best modern practice 
requires an in-built audit system to allow comparison of outcomes from centre to centre within 
countries.  It also allows external benchmarking with centres of excellence in other countries. 
• The NBSP will provide an excellent, intensely quality-assured service for screened women who believe 
that they are healthy and for the treatment of the women who, through screening, are discovered to have 
breast cancer.  It is essential that it be matched by an equally excellent service for those with 
symptomatic breast disease.  It is important to have nationally agreed protocols and guidelines for all 
services and provision of adequate resources to provide a quality service. 
• In the light of the concerns outlined above, the Minister for Health & Children requested that the 
National Cancer Forum produce recommendations on the provision of services for women with 
symptomatic breast disease. 
 
The National Cancer Forum established a sub-group to examine the issue.  The members of the group are 
listed in Appendix 1.  As part of the work, the Regional Directors of cancer services were asked for 
information concerning their current service and their views were sought regarding how the service should 
be developed in their region.  In addition, three members of the sub-group visited each region.  The 
consensus view regarding best practice in the management of breast disease was presented to Regional 
representatives and their views on how this could be achieved in their region were sought.  In each region 
specific issues arose which will need to be dealt with in the process of developing a plan for the breast 
services.  Where possible, difficult issues should be resolved locally.  A list of the places that were visited is 
provided in Appendix 2. 
 
Terms of Reference 
 
To assess the impact on the existing diagnostic services for benign and malignant breast disease in the light 
of: 
• The forthcoming National Breast Cancer Screening Programme; 
• The increase in the target population; 
• The increased awareness of the importance of breast screening;  and 
• The current and evolving technologies in the area of breast screening. 
 
To make recommendations to the Minister for Health and Children on: 
• The diagnostic services for symptomatic breast disease necessary to meet projected increased needs; 
• The need to develop associated services in radiotherapy, medical oncology, counselling and other 
support services; 
• The resources required to develop these services;  and 
• The principles that should underlie the organisation and delivery of services for breast disease. 
 
Requirements for Good Care 
 
There are some requirements that are necessary to provide good care.  There are general requirements, 
principles for diagnosis and principles for treatment.  They are listed below and are based on examination of 
evidence in the literature, which is described in detail in the body of the report. 
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General Requirements (1, 2, 3) 
 
• All women with symptomatic breast disease should have prompt access to high quality multidisciplinary 
care. 
• Although services should be delivered as close to the patient’s home as is feasible, the overriding 
priority should be to provide the best, safest and most effective treatment for women and, in so doing, 
provide the best opportunity for long-term survival to those who are found to have breast cancer. 
• Equipment required to provide an excellent service should be available to units dealing with breast 
diseases. 
• All medical and nursing personnel involved should have specific training in breast diseases in 
designated training centres. 
• Standards of care should follow agreed national guidelines and reflect modern advances. 
• Medical staff involved in this service must undertake regular audit and technology to allow detailed 
audit must be put in place. 
 
Diagnostic Principles (1, 3, 4, 5, 6, 7) 
 
All patients with breast disease should have access to high quality care.  There are a number of principles 
that should govern the diagnosis of breast disease for women who have symptoms suggestive of breast 
disease: 
• It is important that women have access to a uniformly high standard of care.  Over 90% of women who 
attend a symptomatic clinic will not require in-patient treatment.  It is important that the outpatient 
service structure can develop to deal efficiently with the increasing number of women who require this 
service. 
• A Breast Team should be in place to diagnose and treat women with breast diseases. 
• Because of the crucial role of the general practitioner (GP) in the care of patients with breast diseases, 
clear referral guidelines should be sent to GPs for their guidance and approval. 
• At least one referral breast clinic per week for new patient GP referrals should be held. 
Such clinics should not be part of the general surgery clinic.  Only patients with suspected breast disease 
should be seen at this clinic. 
• All investigations required for diagnosis should be available at this clinic. 
• The modern management of breast cancer involves triple assessment, which involves the surgeon 
(surgical oncologist), radiologist and pathologist working together in the clinic. 
• All diagnostic tests should be undertaken at the initial visit in the great majority (90%) of cases.  The 
importance of this principle is emphasised.  Such an arrangement allows speedy reassurance for the 
great majority of patients who do not have cancer but who are anxious (the ‘‘worried well’’).  It also 
avoids the need for multiple visits to hospital, with their associated inconvenience and economic loss. 
• Imaging techniques and expertise (radiographic and radiological) should be subject to the same quality 
assurance criteria as pertains in the NBSP. 
• A pre-operative diagnosis should be made in over 90% of patients with cancer, whether palpable or 
impalpable. 
• For those few patients who require an open surgical operation for diagnostic purposes, the operation 
should be done within two weeks of the decision that operation is needed. 
 
Treatment Principles (1, 2, 3, 4) 
 
A number of principles should govern the treatment of breast cancer: 
• Treatment of breast cancer should be managed by staff with special training and expertise in breast 
disease. 
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• Surgeons treating breast cancer should have undergone formal training in breast disease and should 
work in a Breast Team which has all the necessary facilities and expertise needed for a multidisciplinary 
approach. 
• Consultants in the Breast Team must have dedicated time for attendance at multidisciplinary meetings.  
In addition Breast Care Nurses and trainees in breast surgery must be in attendance at such meetings. 
• In order to collect accurate data preoperatively and to ensure efficiency in administration, data 
management and administrative clerical staff are required for a Breast Team. 
• The ratio of open surgical biopsies that prove benign to the total number of cancers diagnosed should be 
no more than 1:10 (This does not include operations for nipple discharge and previously diagnosed 
fibroadenomas). 
• More than 90% of patients with cancer should be admitted for operation within 3 weeks of the decision 
to operate. 
• Women with breast cancer should have the support of a Breast Care Nurse. 
• The Breast Care Nurse who is a member of the Breast Team should have established links with the ward 
nurses and the other members of the Breast Team. 
• Follow-up arrangements must be defined by protocol and must involve the surgical team. 
• The Breast Team should be involved in biopsies, assessment and management of patients with locally 
recurrent and metastatic breast cancer.  Patients with metastatic breast cancer should remain under the 
care of the Breast Team. 
• All women diagnosed with breast cancer should have their management discussed with a surgeon 
trained in surgical oncology of the breast, a medical oncologist and a radiation oncologist. 
• Involvement in international clinical trials should be recommended, fostered and supported. 
 
Reasons for Proposing Specialist Breast Units 
 
There are a number of reasons why breast services should be delivered through a Specialist Breast Unit. 
• To develop and maintain the skills to deliver a quality service the professionals providing the service 
need to be grouped together to form Specialist Breast Car Teams within Specialist Breast Units. 
• The improved outcome that is found in Units where there is high caseload is thought to be largely 
related to the clinical organisation and multidisciplinary care provided by the service rather than due 
simply to the skill of individual surgeons. 
• It is accepted that a multidisciplinary approach to breast cancer affords women the best therapeutic 
options when diagnosed with breast cancer. 
• The important features of a Breast Care Team are the composition of the team, the way the team works 
and the co-ordination of care that it provides. 
• Treatment frequently involves a combination of surgery, adjuvant systemic therapy and radiotherapy. 
• The multidisciplinary approach enables the clinician, the radiologist and the pathologist to discuss the 
findings together and to reach a consensus on the management of each case according to defined 
protocols. 
• The use of triple assessment substantially reduces the number of unnecessary open surgical operations 
performed both for benign disease and for cancers. 
• High quality pre-operative diagnosis will result in a very large reduction in the number of open benign 
and malignant surgical biopsies. 
a) This affords great benefit in terms of reduced morbidity associated with open surgical procedures 
and considerable reduction in the psychological trauma associated with multiple hospital admissions. 
b) It will also allow good surgical planning, giving an opportunity to counsel patients. 
c) It leads to cost savings and reduced discomfort and inconvenience to the patient 
• Research shows that performance in areas such as mammography and fine needle aspiration (FNA) 
cytology is related to skills, training and expertise. 
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• Adequate multidisciplinary discussion and unit audit can lead to the identification of problems and allow 
for corrective measures to be undertaken. 
• Continuing professional development is a requirement of good practice. 
• Regional unit and quality assurance raises standards.  Breast Units must assess the care they provide in 
terms of process and outcome. 
• Preliminary research conducted by the Women’s Health Council on behalf of the National Cancer 
Forum(8) indicates that what women want from a breast service is 
a) to be seen as soon as possible 
b) to have their tests as soon as possible and preferably in one session 
c) to have their treatment as soon as possible 
d) to have their care provided by a Specialist Breast Care Team 
 
Structure of Specialist Breast Unit (1, 2, 3, 4, 5) 
 
The purpose of developing a new organisational structure for the provision of breast services is to improve 
the quality of care.  The majority of women who have a breast cancer usually discover  it themselves.  When 
a woman first develops breast symptoms she will usually consult her GP, who will in turn seek to refer her 
as quickly as possible to a centre that will provide speedy diagnosis and effective management of her 
complaint.  The modern management of breast cancer entails triple assessment, which involves the surgeon, 
pathologist and radiologist being in the clinic together.  It reduces the number of unnecessary operations 
performed for the benign and malignant breast disease and facilitates rapid diagnosis and better planning of 
treatment.  The proposed structure is based on the guidelines available and the extensive literature on the 
subject, much of which is referenced throughout the report.  The Specialist Unit should be based on a 
population of 250,000 to 300,000 from which it is expected that there will be at a minimum 100 new 
primary breast cancers per annum. 
 
The figure of 100 new breast cancer patients per Breast Unit per year is an indicative figure chosen for the 
following reasons: 
• There is evidence of benefit from specialised multidisciplinary care 
• There is evidence of benefit from large volume case load 
• The figure of 100 applies not merely to the surgeons but to the specialist breast team as a whole. 
The minimum figure of 100 is necessary to justify the investment of specialist time and other resources 
to establish and provide ongoing resources for a modern multidisciplinary Breast Unit. 
A throughput of 100 cases would be expected from a population of 250,000 to 300,000. 
• This level of workload is necessary to sustain the collective expertise of the team. 
• This level of workload is operationally cost-effective for the deployment of a skilled group of people to 
function as a multidisciplinary team. 
• Grouping a number of hospitals together into a ‘‘virtual Breast Unit’’ would not achieve a functioning 
multidisciplinary team. 
• It is not feasible or cost-effective for a group of specialists to meet weekly and invest time and resources 
co-ordinating care if the number of new breast cancer patients falls below two cases per week (100 per 
year). 
• A unit seeing 100 cases of breast cancer per year would see at least 1000 new patients with breast 
symptoms annually.  This level of clinical activity (20 new patients per week) would justify the 
provision of a weekly new patient GP referral clinic, which is essential if women are to be seen without 
delay. 
• Professional consensus in the British Association of Surgical Oncology (BASO) clinical guidelines and 
other documents state the desirability of such a figure. 
• In order to provide the equipment and facilities for an excellent unit, resources are required.  It is not 
feasible to provide this level of resources in many hospitals that do not have the volume to utilise them 
to optimal efficiency. 
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• In some places many of the structures are already in place and it will be relatively east to develop the 
Breast Unit. 
• There is a common belief that people are not prepared to travel outside their own area for health 
services. (9)  However, people are prepared to travel for high quality care, particularly where there is 
recognition that such care is associated with improved survival. 
• The vast majority of women with breast symptoms will not have breast cancer.  They will only require 
one visit to the Breast Unit. 
The main emphasis of the report is on the core services.  It was not possible to deal in as much detail with 
all aspects of the service.  Many important issues such as support services, specialist palliative care services, 
psychological support and social work support may require further examination at a later date. 
 
The main components of a Specialist Breast Unit include core personnel, other essential personnel, 
facilities, equipment and organisational elements. 
 
Core Personnel 
 
The core personnel are the people whose presence is considered to be essential for the Breast Team to work 
effectively in delivering a multidisciplinary service.  Some professionals e.g. the radiation oncologist and 
medical oncologist would not necessarily be based in the hospital where the Breast Unit is located.  
However, they would need to have sessions at the Breast Unit that would enable them to participate fully as 
members of the Breast Team.  Some of the other professionals such as surgeons with an interest and 
expertise in breast disease from other hospitals would also require session at the Breast Unit to enable them 
to participate fully as member of the Breast Team. 
 
The core personnel are as follows: 
• Lead Clinician 
• Breast Surgeons (lead surgeon normally 6 sessions, each other surgeon 3 sessions each) 
• Breast Radiologist (4 sessions) 
• Breast Pathologist (4 sessions) 
• Breast Care Nurse (2 whole time equivalent (WTE) per 100 cancers) 
• Clinic Nurses (1WTE).  They will probably be shared with the general outpatient department. 
• Medical Oncologist 
• Radiation Oncologist 
• Radiographers (2 WTE) 
• One Administrative Officer (Grade VI or VII) 
• Two Clerical Officers (Grade IV or V).  Depending on the workload, three may be required. 
• One Data Manager 
 
Other essential personnel 
 
This includes other staff that are essential for the delivery of a high quality diagnostic and therapeutic 
service.  Women must have access to the expertise of these professionals.  A liaison system, which involves 
good communication and early involvement in the woman’s care, is necessary to ensure that the relevant 
professionals are brought in at the appropriate time. 
• Plastic surgeon 
• Clinical psychologist or psychiatrist 
• Palliative care specialists 
• Physiotherapist/occupational therapist 
• Social worker 
• Clinical Geneticist 
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• Pharmacist 
 
One of the key functions of the breast care nurse is to provide support and counselling to women who attend 
the Breast Unit.  The area of support services such as counselling and social work needs to be examined 
further.  The survey of ‘‘women’s views and perceptions of the symptomatic breast services’’ undertaken by 
the Women’s Health Council which will be submitted to the National Cancer Forum on completion, will 
provide information regarding what women wish to see provided in this area. (8)  Any developments in the 
provision of support services for patients with cancer should be guided by the national review of support 
services that was undertaken for patients with cancer. (10) 
 
Facilities 
 
Care for women with breast cancer should be provided in a friendly, comfortable environment with private 
areas for consultation and counselling.  Consideration should be given to the need for changing facilities and 
the proximity of the various diagnostic and consulting areas.  Necessary accommodation will include: 
• Reception area 
• Waiting room 
• Outpatient clinic accommodation which is close to the imaging area 
• Radiology, including mammography, ultrasound and imaging guidance for localisation procedures. 
• Pathology room or storage of cytology specimens and a microscope 
• Nurse counselling area 
• Inpatient beds 
• Operating time 
 
Equipment 
 
In order to provide high quality multidisciplinary care, basic level of equipment provision is necessary.  This 
includes: 
• Stereotactic mammography machine approximately £130,000 
• Basic mammography unit approximately £50,000 
• Processing equipment approximately £50,000 
• Ultrasound Machine approximately £50,000 
• Information Technology support and database 
• Microscope for Pathologists 
 
The sub-group did not consider it appropriate to attempt to provide detailed costing for the Breast Units.  
Some locations have some of the necessary facilities and staff in place already.  Others would need a large 
injection of resources in order to establish a Breast Unit.  A detailed needs assessment will be required for 
each proposed centre by the Department of Health and Children and the Health Boards to determine the 
exact requirements in each location based on what is already available. 
 
Organisation 
 
The planning of care involves all members of the Breast Team, who must communicate with all other 
professionals who are involved in the woman’s care.  At any particular time in her care there should be a 
principal clinician with whom she relates.  In the early stages this will be the surgeon (surgical oncologist), 
during adjuvant therapy it will be the medical oncologist and the radiation oncologist, and at a later stage it 
may be the palliative care physician.  There should also be a Lead Clinician for the Breast Unit.  The Lead 
Clinician should generally be the surgeon because 
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a) the majority of patients presenting to the Breast Unit do not have cancer and do not require the 
services of a medical oncologist or radiotherapist, but do need the surgical specialist for clinical 
assessment and reassurance 
b) it is the surgeon who is the first point of medical specialist contact with the patient in the hospital 
setting 
c) it is the surgeon who on diagnosis, discusses and undertakes the primary treatment for patients 
who have cancer in the great majority of cases 
 
The Lead Clinician must have the skills to lead the Unit and promote the development of audit, protocols 
and quality assurance measures.  Important elements of the organisation of the Unit are listed below. 
• The range of clinics will include: new patients clinic, results clinic, follow up clinic (general follow up 
clinic, combined clinic for advanced/metastatic disease with medical oncology and radiation oncology, 
clinic for women with low risk of recurrence), family history clinic, mastalgia (breast pain) clinic. 
• Each team should hold weekly multidisciplinary meetings to discuss the clinical management of 
patients.  All relevant member of the Breast Team should attend the meetings. All patients should be 
discussed: new cases pre-operatively and post-operatively; patients with recurrent or advanced disease; 
cases which present difficulties in management; other cases where appropriate. 
• Adequate and clear communication between all those involved in the woman’s care is important. 
• Adequately funded quality assurance is necessary. 
• Audit through collection of data using a specially developed proforma.  Information is co-ordinated by a 
data manager and formally presented and evaluated regularly at the Breast Unit and at National level. 
• All members of the multidisciplinary team should have the opportunity of specialist training. 
• Development of national guidelines and protocols that are agreed nationally should be put in place. 
• Research is fundamental to a high quality Breast Unit and Units should be encouraged to 
a) develop clinical research activity 
b) liaise with existing academic centres where basic research is conducted 
c) become involved in clinical trials 
• Clinical trials are the basis for the development of the knowledge which leads to the best treatment 
methods for breast cancer.  Breast Units should support clinical research and should participate in a 
programme of multi centre clinical research and clinical trials aimed at improving the treatment of breast 
cancer. 
The relationship between NBSP and the symptomatic services requires detailed study and analysis.  It is 
essential that any arrangement makes effective use of all resources and ensures equity of access and quality 
of care for both groups of women.  Detailed examination of the various models in place internationally is 
required with regard to how the two services might be linked. 
 
Current Situation 
 
While good care is currently being provided, there are infrastructural elements, which if developed would 
lead to an improvement in the quality of care.  Based on the information provided by the Regional Cancer 
Directors and the visits to each region the main findings were: 
• Variable practices in the type of surgery being performed 
• High rate of open biopsy for benign disease 
• High rate of open biopsy for malignant disease 
• High rate of benign to malignant biopsies 
• Lack of pre-operative diagnosis 
• Lack of pre-operative treatment planning 
• No surgical training programme for breast disease exists in the country  
• Major issues in surgery 
a) large variations in the type of surgery being carried out on the breast 
b) lack of accuracy or protocols in assessment of tumour margins 
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c) variations in the surgical operations on the axilla. 
• Unequal access to pathology services with large variation in the detail of reports by pathologists, for 
example 
a) variable accuracy of pathology assessment of tumour margins, 
b) variation in the detail of reporting numbers of axillary lymph nodes and 
c) lack of uniform proformas and standard protocols 
• Unequal access to ultrasound facilities 
• Mammography with no dedicated processing 
• Variable and unstructured GP access to mammography 
• Variable and unstructured GP referral and follow-up 
• Radiotherapy/medical oncology 
a) access to adjuvant therapy difficult 
b) where it exists it is sub-optimal 
c) consultant availability very variable 
• Lack of breast clinics; women seen as part of general surgical clinic 
• Multidisciplinary meetings are uncommon 
• Clinical trials uptake is minimal, and the number of patients recruited into clinical trials is low 
• No organisation in management of metastatic breast cancer 
• Follow-up variable 
• Data not collected to enable evaluation of quality of care 
 
Recommendations 
 
Based on the requirements for good care, the following recommendations are proposed. 
• Specialist Breast Units should be established throughout the country.  These units should be fully 
staffed and resourced in order to deal with patients with breast cancer. 
• The Specialist Breast Unit should be based on a population of 250,000 to 300,000 from which it is 
expected that there will be, at a minimum, 100 new primary breast cancers per annum. 
• There should be at least two surgeons attached to the Breast Unit.  The lead surgeon should normally 
have a minimum of six fixed sessions and other surgeons attending with a special interest in the breast 
disease should have a minimum of a least three sessions in the Breast Unit, covering GP referral clinics, 
follow up clinics, breast operating lists, attendance at multidisciplinary meetings and weekly combined 
breast clinics. 
• Requirements for the training of a surgeon with a special interest in breast disease and the arrangements 
needed for a designated training centre have been submitted as recommendations to the Royal College 
of Surgeons in Ireland. 
• Two nominated radiologists trained and with continuing experience in breast disease.  The must be 
available for reading mammograms and carrying out ultrasound and stereotactic investigations required 
at new referral clinics.  They must be available to report mammograms on all cases arising from the 
breast diagnostic work of the unit and to attend the multidisciplinary meetings and audit meetings.  In 
some areas it may not be feasible to have two radiologists based in the hospital and special arrangements 
may be necessary.  Radiologists should have the opportunity to attend specialist training courses similar 
to training courses available to radiologists working in the UK. 
• Two pathologists will be responsible for all breast pathology and cytology.  They must have dedicated 
sessions to attend multidisciplinary breast meetings and audit meetings. 
• At least two breast care nurses available to counsel and offer practical advice and emotional support to 
newly diagnosed patients, discuss treatment options with them and provide a prosthetic service. 
• The medical oncologist and radiotherapist must arrange the appropriate delivery of radiotherapy and 
chemotherapy.  They should hold joint clinics with other members of the breast care team and must take 
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part in multidisciplinary and audit meetings.  While they may be based at another hospital they should 
have dedicated sessions at the Breast Unit. 
• Breast diagnostic radiographers with necessary training and expertise in mammography.  They must 
hold a certificate of competence in mammography. 
• Clerical support including two full time secretaries of high grade and an administrative officer to 
organise the clinic and a data manager in each unit. 
• Each medical discipline (surgical oncology, medical oncology, radiation oncology, orthopaedic surgery, 
and specialist palliative care) should have written protocols of management of patients with breast 
cancer. 
• Management of all patients with breast cancer should be discussed at a multidisciplinary meeting. 
• There must be swift effective communication between the Specialist Breast Unit and the GP. 
There should be minimal delay between referral of a woman with a lump from the GP and an outpatient 
appointment and between first consultation and communication of the diagnosis with the patient and to 
the GP. 
• Patients should be recruited into clinical trials where feasible. 
• Modern methods of audit and monitoring of outcomes must be put in place.  This requires effective data 
management.  It requires both routine audit and the basic infrastructure for collection of data concerning 
patients, their disease, treatment and outcomes, and systematic reporting and recording of pathology 
data. 
• A Breast Unit Annual Report, containing data according to protocol from each Breast Unit should be 
prepared by a designated lead person in each Unit. 
• All Units should be interlinked so that identified information is collected from each centre in such a 
way as to be amenable to comparison among centres and to external audit. 
• All Breast Units should combine annually for an audit/outcome meeting to monitor and verify that 
audit standards are being reached and maintained. 
• A National Annual Report should be produced 
• Annual Quality Assurance meetings among all Units are necessary in the same way as in screening 
programme. 
• Individual sub-speciality audit should be performed.  Each group should analyse its own performance 
indicators and agree protocols. 
• A national executive multidisciplinary committee, whose function is to analyse the activities of the 
Breast Units, should meet at least annually. 
• A centralised Quality Assurance Office should be established and staffed appropriately with a data 
collection and evaluation manager supported by clerical staff.  It should 
a) collect data from the regional Breast Units, 
b) co-ordinate and organise the annual audit meeting and 
c) produce a National Annual Report 
• A Reference Unit should be established.  The function of the Reference Unit would be to  
a) act as a facilitator and advisor to other Units, particularly in unusual or complex cases 
b) promote research activity among Units 
c) be responsible for additional specialist training 
d) house the Quality Assurance Office 
• A Breast Cancer Multidisciplinary Advisory Group should be established to  
a) advise the Minister for Health and Children on the functioning of the Breast Units 
b) to make recommendations concerning the quality of care in each Unit 
c) keep under review developments in research in the area of breast cancer 
d) provide advice on service changes that may be required as a result of research developments 
e) provide advice on new or unusual interventional procedures such as vacuum assisted biopsy 
techniques.  These techniques are being developed in screening services.  Resources should be used 
in the most efficient manner and they should be centralised as much as possible. 
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• Organisation of the Breast Unit should include ensuring that transport arrangements are in place to 
facilitate women residing in areas that may pose logistic difficulties in travelling to the Unit.  This could 
include consideration of initiatives such as: (11) 
a) Van/bus assistance services, 
b) Taxi services at reduced fares, 
c) Financial support to individuals who provide informal transportation assistance to patients 
d) Voluntary transport assistance to women via cancer support groups. 
• Each Health Board should examine the geography, road system and population distribution of their own 
region in order to identify subgroups of women who may have particular difficulties with transport that 
would deter them from availing of the services provided by the Breast Unit 
• While it may be possible for follow-up treatment to be carried out in hospitals other than the Breast 
Unit, primary surgery and diagnostic procedures must be undertaken at the Breast Unit. 
• If difficulties are encountered in implementing these recommendations the National Cancer Forum 
should be consulted and changes must not be made to the recommendations without approval of the 
National Cancer Forum. 
 
Location of Units 
 
South Eastern Health Board 
 
The population base justifies one unit.  The South Eastern Health Board has ratified the decision to 
centralise services in Waterford.  A significant amount of forward planning at an administrative and 
organisational level has been carried out within the region.  A formal plan for the region has been presented.  
This plan is in keeping with the guiding principles.  It is recognised that other acute hospitals in the area 
have surgeons and other professionals who have an interest in breast disease who could travel to the centre 
to carry out breast work there.  Such an arrangement would neatly combine the maximum possible use of 
resources and personnel whole maintaining job satisfaction and expert individual attention.  Additional posts 
and sessional commitments will be required to allow for surgical sub-specialisation. 
 
Southern Health Board 
 
The population base in the Southern Health Board is large enough to support two units. Based on the 
population, it seems appropriate to have two centres in Cork  City as no centre outside the city has sufficient 
population to justify a full unit. 
 
The South Infirmary has the largest number of cancers seen each year.  It has a clinical and radiological 
expertise developed over 15 years.  It provides an excellent, integrated, efficient and patient-oriented 
service, despite the fact that it does not have on-site pathology.  This would appear to be the appropriate site 
to base a Breast Unit.  Cork University Hospital (CUH) has established a breast clinic recently, but there is 
not on-site mammography. One consultant surgeon at the hospital undertakes breast surgery.  This is not 
ideal for full coverage of the service.  Radiotherapy will be undertaken there and this needs to be funded 
adequately in order to provide a good service. 
 
Over the past year, the number of breast cancers seen at CUH has increased.  Based on data supplied by the 
hospitals, it is estimated that CUH and the South Infirmary have seen between 80 and 100 breast cancers per 
annum. Recently there has also been increased co-operation and collaboration between the two hospitals.  
Based on the population of the Southern Health Board, a second unit is required.  It is recommended that it 
be based in CUH.  It is recommended that the expertise that exists in Tralee should be utilised in the new 
Breast Unit.  Professionals with an avowed and continuing interest form other hospitals should be allowed 
to participate.  This will entail making provisions for their sessions at the base hospital to be covered while 
they are undertaking sessions at the Breast Unit. 
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Mid-Western Health Board 
 
The population of the Mid-Western Health Board only justifies on Unit.  A large breast clinic has been 
established in the Limerick Regional Hospital where surgeons from Nenagh, Ennis and St John’s Hospital 
have come together to provide the service.  The Health Board population justifies one unit.  The unit should 
be placed in the Limerick Regional Hospital, which has a lot of the activity and ancillary requirements 
needed.  A breast clinic has been operational in Ennis and the surgeons who run the clinic in Ennis should 
be incorporated into the centre in the Regional Hospital.  If such voluntary involvement arises, there should 
be practical support regarding coverage of their other clinical activities at Ennis Hospital while they are 
away from base conducting breast work in the Unit.  This may mean the appointment of an additional 
consultant surgeon in the region. 
 
Western Health Board 
 
The population of the Health Board justifies one Unit.  The University Hospital in Galway has been 
delivering a service for a long time under difficult circumstances.  They are experiencing large demand 
relative to resources.  The implementation of increased support is an immediate requirement because their 
workload is already present and the need is immediate.  The University Department of Surgery has 
developed a strong clinical service and supplemented it by enterprising clinical research.  There is an 
immediate need for another breast surgeon and support services. 
 
There is not sufficient population to justify a Unit in Castlebar.  The staff at Castlebar Hospital should be 
encouraged to contribute to the Galway Unit if they wish to do so.  As is being proposed for the Mid-
Western Health Board and the Southern Health Board, if professionals from Castlebar wish to become 
involved in the Breast unit in Galway, provision should be made for their sessions at the base hospital to be 
covered while they are undertaking sessions at the Breast Unit. 
 
North-Eastern Health Board 
 
The population supports only one Unit in the North-Eastern Health Board.  Based on the principles 
discussed in this report, there is no justification for two Units.  The most densely populated area is in the 
southern aspect of the Health Board in Louth and Meath.  This is likely to expand over the coming years.  
Individuals with an expressed interest and expertise in breast services should be incorporated into the Breast 
Unit.  They need to have adequate support in order to cover their regular duties while they are away from 
their own base hospitals.  People should be allowed to become involved, provided they meet with the audit 
and CME needs.  Some facilities already exist in Drogheda and this would appear to be an appropriate 
location for the Breast Unit. 
 
North-Western Health Board 
 
The population of this Health Board supports only one Unit.  Geographical considerations dictate that an 
innovative approach is required in order to ensure that services are available to patients in acceptable 
settings as far as possible.  In Letterkenny, there is a committed group of people providing a service but they 
do not have a large enough volume of patients with breast cancer.  They will need to link with Altnagelvin 
Hospital in Derry in order to increase their caseload, experience, expertise and formal cross-cover.  If 
collaboration between Derry and Letterkenny occurs, it should be a true liaison.  Scope exist for such a 
liaison to be formalised.  There are strong clinical links between the two hospitals and also between 
Letterkenny and Belfast City Hospital.  These links have been establishes and are being developed further 
and provide the impetus for a formal arrangement to be established.  Northern Ireland population interests in 
the development of this Unit should be explored with Northern Ireland health authorities.  This sort of 
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decision has to be supported at the highest political level so that the highest standards can be maintained and 
for the ease of access and administrative efficiency. 
Sligo has insufficient population to justify a unit.  There is currently little infrastructure in Sligo and 
considerable resources would be required in order to set up a Breast Unit there.  However, the only realistic 
proposal would be that, in this particular case, crossing Health Board boundaries could be justified.  If the 
population of Sligo, Leitrim, West Cavan and part of Mayo are incorporated, it is estimated that the 
population would be adequate to provide a sufficient volume of patients. Therefore it is recommended that a 
Breast Unit be established in Sligo serving those areas.  This is an innovative proposal that will require the 
involvement and agreement of the CEO’s and Board of each of the relevant Health Boards.  There will need 
to be agreement that patients cross traditional Health Board boundaries. 
 
Midland Health Board 
 
The population of the Midland Health Board marginally supports one unit.  There is a small breast service 
currently in Mullingar.  There is no service in Tullamore.  Patients currently travel to Portlaoise where a 
long established unit with considerable clinical expertise and a great deal of ancillary patient-focused and 
orientated support at medical and nursing level has been developed over many years.   Bearing in mind that 
the great majority of women attending the clinic will not have cancer, it is not essential to locate the Breast 
Unit in the designated regional cancer centre.  Because the delivery of breast services can largely be 
delivered in non-emergency settings, it is unlikely to require high dependency support.  However, there is 
concern that the peripheral location of Portlaoise in the Health Board might militate against achieving the 
critical mass of patients required for the Unit.  There would be a case to be made for locating the Breast Unit 
in Tullamore because of its geographical location in the Health Board and because this would fit in with 
previous decisions made by the Health Board regarding the organisation of oncology and pathology 
services.  It is essential that the available expertise that already exists within the Health Board should be 
fully utilised in the new Breast Unit and professionals with an avowed and continuing interest from the 
other hospitals should be allowed to participate.  This will entail making provision for their sessions at the 
base hospital to be covered while they are undertaking sessions at the Breast Unit.  Should the decision be to 
locate the Breast Unit in Tullamore then the existing and longstanding expertise of those involved in the 
Portlaoise unit should provide the basis of the service in Tullamore.  This will ensure that a highly valued, 
quality service will be provided to all women in the Midland Health Board region. 
 
Eastern Health Board 
 
In the Dublin region, it is proposed to establish two Breast Units on the north side and three on the south 
side of the city.  One of the Units on the north side should be located in the Mater Hospital.  The other Unit, 
bases at Beaumont Hospital should involve the participation of interested staff from the James Connolly 
Memorial Hospital in Blanchardstown.  On the south side of the city, separate Breast Units should be 
located in St Vincent’s University Hospital, St James’ Hospital and the Tallaght Hospital. 
 
The Master Hospital already houses the Eccles Screening Programme and is expected to treat 150 patients 
per year in the prevalent round.  It is appropriate to utilise the expertise at this site for patients in the Breast 
Unit.  It is important to have a Breast Unit in a hospital with a screening unit because follow-up of breast 
cancer detected by screening takes place in the Breast Unit.  Many of the staff and most of the infrastructure 
required are already in place. 
 
James Connolly Memorial Hospital and Beaumont Hospital each have breast clinics.  The catchment 
population does not support two separate Units.  There are committed professionals who have academic 
links in both hospitals.  They are prepared to work together to develop a Breast Unit on one site but availing 
of the expertise of both hospitals.  This initiative should be supported.  Neither hospital has adequate 
facilities or equipment.  It is proposed that the Unit be sited at Beaumont Hospital and should involve 
relevant staff from James Connolly Memorial Hospital.  It is proposed that another consultant surgeon with 
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a special interest in breast disease be appointed.  The consultant would have general surgical session in 
James Connolly Memorial Hospital and specialised breast sessions including theatre sessions in Beaumont 
Hospital. 
 
Tallaght is a new hospital and is developing its breast services.  It is located in an area with a very fast 
growing catchment population.  The expanding population base and catchment would indicate that locating 
a Unit in Tallagt would be reasonable.  Many of the pathology and radiology requirements are available. 
 
St James’ Hospital has a newly established well-audited breast clinic.  Most of the key personnel are 
available, as are the back-up facilities.  Its catchment area and the service it provides to the inner city 
population justify a Breast Unit in this hospital. 
 
The first breast clinic in the country was established in St Vincent’s University Hospital and it has been 
providing a symptomatic breast service for twenty years.  The hospital currently treats the largest number of 
breast cancers of any institution in the country.  It is to be one of the screening locations for the NBSP and 
will have approximately 150 extra breast cancers from screening.  There is a need for significant investment 
in infrastructure but many of the requirements are in place. 
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CHAPTER 1 
Breast Cancer 
 
 
Background  
 
Breast cancer is the most common cancer in women (after non-melanoma skin cancer).  The risk to a 
woman of developing breast cancer before age 75 years is 7.9% and the risk of dying of breast cancer before 
age 75 is 2.8%. (12) The mortality/incidence ratio is 38%. (12) Approximately 1670 women are diagnosed 
with breast cancer each year and 650 women die from the disease. (12)  Many more women attend the health 
services with breast symptoms, which require investigation but do not turn out to be breast cancer.  These 
women suffer the same anxieties before diagnosis and deserve to have access to an equally high quality 
service. 
 
Prevention 
 
Hereditary Breast Cancer 
 
While the causes of breast cancer are not fully understood, some women appear to be at higher risk.  A 
distinction can be made between familial and hereditary breast cancer.  Familial breast cancer is where first 
degree relatives have had breast cancer whereas hereditary breast cancer  relates to a genetic aberration 
giving rise to breast cancer typically occurring at an early age and associated with a high incidence of 
bilateral breast cancer and other tumours.  Genetic factors contribute to approximately  5% of breast cancers 
and mutations in the BRCA1 and BRCA2 genes are probably accountable for the great majority of 
genetically determined breast cancers.  Many uncertainties exist concerning BRCA mutations.  The lack of 
effective preventive methods for these women complicates recommendations for testing and follow up. (13)  
Ongoing and future chemoprevention trials might have an important impact upon the use of genetic 
information. (14)  Genetic testing for breast cancer is currently not advisable as a routine until more 
information is available concerning quantification of the risk factors, possibilities of prevention and specific 
treatments.  Specific guidelines concerning referral of Breast Clinics relating to family history are also 
difficult to recommend.  The general recommendation at present is that when the relative risk of breast 
cancer is three times that of the general population, Specialist Breast Clinic referral is advisable.  People in 
this category would be suitable to be invited to participate in clinical trials of breast cancer prevention. 
 
Chemoprevention 
 
Tamoxifen, an anti-oestrogen preparation was, in the 1970s found to be valuable in the treatment of patients 
with advanced breast cancer and later was used in patients with early breast cancer to prevent recurrence.  
Its role in this situation has been established not only in reducing the incidence of recurrent cancers but also 
in preventing new cancers in the opposite breast.  In recent years three important studies have been reported 
on the use of Tamoxifen in well women in order to prevent cancer.  One of the studies indicated a 45% 
reduction in breast cancer incidence in people who used Tamoxifen to prevent the disease (15) but two other 
smaller studies failed to demonstrate a protective effect of Tamoxifen. (16, 17)  The issue is unresolved 
because the follow-up time in these studies is too short to make a definitive statement on the value of this 
agent.  Trials of Tamoxifen prevention are continuing. 
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Relationship between stage and outcome 
 
A direct relationship exists between the stage at which breast cancer is diagnosed and treated and the long-
term survival.  The staging of breast cancer is based on the TNM classification i.e the size and extent of the 
tumour (T), the presence and extent of involvement of the cancer by the axillary lymph nodes (N) and the 
presence or absence of spread of the cancer to distant sites (M for metastases).  Thus for breast cancers of 5 
millimetres or less in diameter where the lymph nodes are free of tumour, complete cure after adequate 
treatment is to be expected in over 95% of cases.  For tumours between 5 and 10 millimeteres in size, the 
long term cure rate is around 90%.  With increasing size of tumour and with axillary lymph node 
involvement, the long term survival rates are much lower.  However even in patients with relatively large 
tumours and involved lymph nodes, the long term survival is in the region of 50%.  Because of the high 
probability of cure for patients with small tumours, increasing efforts are being made to identify breast 
cancers when they are small.  Early diagnosis is important. 
 
Breast Screening 
 
Screening for breast cancer aims to reduce premature deaths from breast cancer by identifying and treating 
the disease effectively when it is in the early stages.  High quality mammography can detect cancers before 
they become apparent and before they have other clinical features.  Early and effective treatment of tumours 
at this stage provides the best chance of  long term cure and, in the great majority of cases, allows such cure 
to be brought about without the need for removal of the breast (mastectomy).  The NBSP, recently 
introduced, is directed at apparently well women between the ages of 50 and 65 years in order to identify 
and treat small tumours before they become discernible on physical examination.  The NBSP is not, at this 
stage, being extended to younger women because clear proof of the value of population based breast 
screening has, up to now, been confined to women over the age of 50 years.  The NBSP is based on high 
quality mammography, speedy access to expert care, high quality communications and excellence in record-
keeping and audit.  It is clearly essential that an excellent programme for women who believe themselves to 
be free of breast disease must be matched by an  equally excellent system for women with symptoms of 
breast disease. 
 
Screening for breast cancer aims at identifying the disease at an early stage in order to reduce mortality.  It 
is thus based on early detection rather than primary prevention.  There have been numerous studies on 
population based screening mammography.  The have been randomised controlled trials and case control 
studies since 1963.  Estimates of mortality reduction have been variable.  Not all studies have demonstrated 
a statistically significant mortality reduction but they have all demonstrated a downward trend in mortality.  
A meta-analysis of screening mammography published in 1995 indicated a mortality reduction of the order 
of 25% in women screened between 50 and 74 years. (18)  The Department of Health and Children has 
determined that Phase 1 of the NBSP should commence in the Eastern Health Board, North Eastern Health 
Board and Midland Health Board areas.  Women between 50-64 years will be invited for two-view 
mammography at two yearly intervals.  Th Programme will extend to the rest of the country following 
evaluation of Phase 1.  This is a population based screening programme.  It is essential that all understand 
that this service is offered to women without symptoms in the appropriate age group.  Eligible women will 
be identified by compiling a register.  Various government departments and statutory bodies are sharing 
information with the screening programme;  these include the VHI, GMS and Department of Social 
Welfare.  Women will be asked to self-register if they are in the appropriate age group.  Opportunistic 
screening outside the NBSP should be discouraged as the NBSP becomes established. 
 
It is imperative that women with symptoms of breast disease are referred to diagnostic breast clinics.  This is 
important, as mammography alone is not appropriate for women who have symptoms.  Women with 
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symptoms must have the benefit of triple assessment, (clinical examination, imaging and pathological 
assessment).  No single test undertaken affords sufficient safeguard against breast cancer being missed.  
When all three tests are used in the appropriate clinical setting, diagnostic sensitivity and specificity rise.  It 
is important to ensure that women themselves understand that screening is for healthy women without 
symptoms.  They must not self-register when they discover symptoms but rather should attend a diagnostic 
symptomatic clinic, if their GP thinks appropriate. 
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CHAPTER 2 
Specialist Breast Unit 
-Outpatient Facility 
 
Diagnostic Principles (1,3,4,5,6,7) 
 
All patients with breast disease should have access to high quality care.  There are a number of principles 
that should govern the diagnosis of breast disease for women who have symptoms suggestive of breast 
disease: 
• It is important that women have access to a uniform high standard of care.  Over 90% of women who 
attend a symptomatic clinic will not require in-patient treatment.  It is important that the outpatient 
service structure can develop to deal efficiently with the increasing number of women who require this 
service. 
• A Breast Team should be in place to diagnose and treat women with breast diseases. 
• Because of the crucial role of the general practitioner (GP) in the case of patients with breast diseases, 
clear referral guidelines should be sent to GPs for their guidance and approval. 
• At least one Referral Breast Clinic per week for new patient GP Referral should be held.  Such clinics 
should not be part of the General Surgery Clinic.  Only patients with suspected breast diseases are seen 
at this clinic. 
• All investigations required for diagnosis should be available at this clinic. 
• The modern management of breast cancer involves triple assessment, which involves the surgeon, 
radiologist and pathologist working together in the clinic. 
• All diagnostic tests should be undertaken at the initial visit in the great majority (>90%) of cases.  The 
importance of this principle is emphasised.  Such an arrangement allows speedy reassurance for the 
great majority of patients who do not have cancer but who are anxious (the ‘‘worried well’’).  It also 
avoids the need for multiple visits to hospital, with their associated inconvenience and economic loss. 
• Imaging techniques and expertise (radiographic and radiological) should be subject to the same quality 
assurance criteria as pertains in the NBSP. 
• A pre-operative diagnosis should be made in over 90% of patients with cancer, whether palpable or 
impalpable. 
• For those few patients who require an open surgical operation for diagnostic purposes, the operation 
should be done within two weeks of the decision that operation is needed. 
 
Patient Identifies a Problem 
 
The majority of women who have a breast cancer (74%) usually discover it themselves. (19)  While regular 
breast self examination is not advocated as a screening method, it is useful for women to become familiar 
with their own breasts and how they change at different times of the month.  This will enable them to judge 
any changes that may occur in the breast.  Women may notice 
• a change in the breast (size or shape, dimpling of the skin, thickening), 
• change in the nipple (inverted, thickening, bloodstained discharge, rash) or 
• change under the arm (swelling of armpit). 
Finding a breast lump can be frightening.  The anxiety it causes may lead to inaction and the woman may 
delay going to her doctor.  The Caring for Woman with Cancer (CAWAC) survey found that 24% of 
women with breast symptoms waited a month or more before presenting to their doctor. (19)  With the 
establishment of  the NBSP, it is possible that some worried women with symptoms may register for 
mammography instead of seeking medical help.  Women with breast symptoms should attend their GP.  If 
referral is required they should be referred directly to a breast clinic rather than merely for mammography. 
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There are substantial personal costs for women who are found to have a breast problem.  Such costs are  
incurred both in women where the breast problem is identified through screening or because of symptoms. 
(20)  Such costs may act as a barrier and disincentive to seeking diagnosis and treatment.  This must be borne 
in mind by any health service provider wishing to provide an equitable service that will be accessible to all 
women. 
 
Requirements 
 
• Before arriving at the clinic a woman should have an idea of what is ahead of her.  This includes 
information about the various procedures that may be undertaken and the length of time they are likely 
to take.  Such clinic visits can take 2-3 hours if all the diagnostic pathways are required. 
• Education is necessary for women in the general population and for professionals. 
• Consideration should be given to the format of the information produced and its dissemination to ensure 
that it can be easily accessed, understood and absorbed by women, including those with disabilities and 
low literacy levels.  The needs of marginalised groups such as travellers, ethnic minorities etc. should be 
met in any information campaign strategy. 
• Guidelines are needed for GPs to improve their knowledge and to facilitate communication with the 
Breast Unit. 
 
Reasons and Evidence 
 
• Breast disease is common.  Women need to be informed as to what breast cancer is and what they need 
to do once they develop symptoms. 
• The majority of women (80%) know little about cancer before their diagnosis. (19) 
• Their main source of knowledge appears to be TV, radio, magazines,  books and personal contacts.  
Only 14% of women with cancer identify health professionals and only 3% identify voluntary 
organisations as a source of information on cancer. (19) 
• Women need to understand that the earlier the diagnosis is made the better the outcome. 
• Women should be empowered to seek help early when appropriate. 
• They should have full knowledge of all investigations and treatment options. 
 
Patient attends GP 
 
When a woman first develops breast symptoms she will usually consult her GP, who will in turn seek to 
refer her as quickly as possible to a centre that will provide speedy diagnosis and effective management of 
her complaint. 
• The type of symptoms among women who are referred by GPs may vary from breast pain to obvious 
cancers. 
• The role of the GP includes referring women promptly to the most appropriate clinic (deciding where 
the patient should be referred and also the degree of urgency of such referrals), and providing ongoing 
care to women with breast cancer including re-referral where necessary. 
• The GP requires speedy, direct and focused communication from the Specialist Breast Clinic. 
 
Increased awareness of breast diseases has led to an increased number of women presenting to the GP with 
breast symptoms to seek advice.  There has been a corresponding increase in referrals to surgical clinics and 
to breast clinics in Ireland.  GPs may experience difficulties with regard to the initial diagnosis, referral and 
long term follow up of the woman.  They need clear advice regarding which women need to be referred and 
which women can be safely dealt with by the GP.  Women who can be managed by their GP would include: 
(a) women with minor or moderate degrees of breast pain who do not have a palpable distinct lump 
(b) women under the age of 50 years with multi-ductal nipple discharge which is not troublesome nor 
blood-stained. 
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(c) Asymptomatic women with a minor family history who are at low risk of developing breast cancer and  
(d) Young women with tender nodular breasts and older women with symmetrical nodularity who have no 
focal lesion demonstrable. 
 
This will only be possible if there are clear guidelines, training and support systems in place for GPs.  There 
should be access to the clinic for these women if the GP requires advice. 
 
Requirements 
 
• GPs require clear guidelines and protocols to assist them in managing women who present to them with 
breast symptoms and in ensuring that they have rapid access to appropriate care. 
• Direct access for GP requested mammography is not recommended and this should not be necessary if 
access to the breast clinic is adequate.  The Breast Unit should have clear and unambiguous 
arrangements for rapid referral from GPs. 
• Clear links must be established with the Breast Units.  GPs should be able to ensure that the women who 
need to be seen urgently (e.g those with a palpable breast lump) are seen within 10 working days at a 
multidisciplinary clinic and that others (such as with breast pain) are seen within a reasonable time 
frame. 
• This will entail developing in partnership with GPs, agreed protocols for referral and the identification 
of a contact person within the Breast Unit with whom the GP can liaise. 
• The issue of an ‘‘urgent’’ referral is entirely a decision for the GP and should be reserved for those 
patients whose symptoms and signs are highly suggestive of breast cancer.  Guidelines will help the GP 
decide which patients with breast symptoms warrant referral and which can be managed safely by the 
GP. 
• The term ‘‘urgent’’ should only be used in patients with symptoms highly suggestive of breast cancer.  
These include 
(a) discrete lump in a woman over 40 years of age, 
(b) skin ulceration 
(c) distortion of the breast or nipple-areolar complex 
(d) an intradermal nodule 
(e) blood stained nipple discharge. 
• Breast Unit protocols should include provision for communication to the GP of the diagnosis and 
proposed treatment. 
• Reports should be sent to GPs within 1 week.  Sufficient support staff are needed to enable this to 
happen. 
• A close working relationship with the Breast Unit will enable the GP to confidently inform the woman 
regarding what awaits her at the clinic. 
 
Reasons and Evidence 
 
• It is inevitable that the introduction of the NBSP will result in a greatly increased pressure being placed 
on GPs to provide advice and guidance to women with breast problems. 
• The National Health Service Breast Screening Programme, in the UK, in conjunction with the Cancer 
Research Campaign developed a booklet entitled ‘‘Guidelines for Referral of Patients with Breast 
Problems’’. (21)   They were designed to assist GPs to make referral of patients with breast symptoms 
easier, more effective and to make the process more efficient with the ultimate objective of improving 
the standard of care.  There is evidence that they resulted in better referrals to the breast services. (22) 
• Avoiding short delays reduces anxiety and avoiding long delays improves survival.  During the period 
between initial suspicion of breast cancer and diagnosis, most women are anxious.  Patient surveys show 
that women are particularly concerned about delay between initial presentation to the GP and diagnosis. 
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• The CAWAC survey found that while 39% received their diagnosis within one week and 31% received 
their diagnosis in 2 or 3 weeks, almost one quarter (23%) of breast cancer patients waited one month or 
more for their diagnosis. (19) 
• GPs have a heavy worklaod.  Any assistance that can be provided to aid them in the management of  
breast cancer will be welcomed. 
• Provision of guidelines will make referral decisions easier and provide a higher standard of care for the 
patient. 
• If surgeons receive more appropriately worded referral letters it will be easier to prioritise patients 
without delaying the diagnosis for women with cancers. 
 
Referral to Specialist Breast Unit 
 
This section outlines what should happen when a woman is referred to a Specialist Breast Unit.  On arrival, 
the clinic secretary welcomes the woman.  Details are taken and she is shown into the comfortable waiting 
room containing information materials.   The modern management of breast cancer entails triple assessment, 
which involves the surgeon, pathologist and radiologist working together in the clinic. 
• The clinician takes a good history and conducts a thorough physical examination. 
• Most women with a discrete abnormality on clinical examination will require mammography and/or 
unltrasound.  The radiologist gives an immediate report to the clinician. 
• If there is a palpable lesion, following imaging, the clinician will take a core biopsy or cytology.  Local 
expertise will dictate which is performed.  The pathologist provides an immediate result for cytology but 
core biopsy results takes 24 hours. 
• If the lesion is impalpable the radiologist will undertake the biopsy by stereotactic methods. 
• Having had the biopsy, the woman is brought back to the clinician and in the presence of the breast care 
nurse she is given an explanation of the findings. 
 
Where appropriate, the clinical, radiological and pathological findings should be discussed at the clinic by 
the consultant surgeon, radiologist, and pathologist.  The diagnosis and provisional treatment plan should be 
agreed.  The diagnosis and treatment should be discussed with the patient by the consultant surgeon.  The 
clinician, on reviewing the results may reassure the woman and discharge her back to the care of her GP if 
she does not require further intervention or she may be asked to return to the results clinic to receive the 
result of the core biopsy.  If a diagnosis of breast cancer is made at the first visit the diagnosis and treatment 
should be discussed with the patient by the consultant surgeon.  A breast care nurse should be present as she 
has an important role to play in discussing the patient’s concerns and providing necessary information.  
Some clinicians consider it preferable to bring the patient back on a second occasion to receive the diagnosis 
and to discuss options because they consider this to be less traumatic for the woman. 
 
Requirements 
 
Organisation of Care in the Breast Unit (1,2,3) 
 
All women with breast disease should come to a fully equipped, multidisciplinary Specialist Breast Unit.  
The majority of women who require assessment for suspected breast cancer do not have cancer and will not 
require extensive facilities.  However, they do require specialist doctors and other professionals so that they 
can be quickly reassured at a single visit. 
• At least one new patient GP referral clinic must be held each week (at which only breast cases are seen) 
• Each new GP referral clinic should see approximately 15-20 cases per session.  It should be a consultant 
delivered service.  Some Units may require more clinics to cope with the workload. 
• Apart from the new patient clinic for GP referrals, other clinics will also be required.  They include a 
results clinic, follow up clinic (general follow up clinic, combined clinic for advanced/metastatic disease 
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with medical oncology  and radiation oncology, clinic for women with low risk of recurrence), family 
history clinic, mastalgia clinic. 
• All necessary investigations should be undertaken at this visit. 
• Care should be prompt, multidisciplinary and delivered in a sympathetic manner. 
• Each clinic should have appropriate facilities for mammography and ultrasonography with the Specialist 
Breast Unit Radiologist in attendance. 
• The modern management of breast cancer involves triple assessment, which involves the surgeon, 
radiologist and pathologist working together in the clinic.  All facilities and staff needed to carry out the 
appropriate test should be in close proximity to the diagnostic clinic. 
• The clinical, radiology and pathology findings of all new patients with breast cancer should be discussed 
at a weekly multidisciplinary team meeting. 
• The results of the tests should be given to the patient within 5 working days.  Women who do not have 
breast cancer can be reassured and treated if necessary, while those who do may proceed rapidly to 
treatment. 
• Since the majority of women (95%) do not have breast cancer, GPs need to be actively involved in the 
programme and take care of the women who are diagnosed as having benign lesions.  While the 
specialists at the breast clinic can say that the tests are clear, they cannot guarantee that the woman will 
not develop cancer in the future.  Therefore continuing surveillance is required. 
 
Surgery (3) 
 
• A definite pre-operative diagnosis should be available for 90% of women. 
• Women requiring surgery for diagnostic or therapeutic purposes should be given a specific date for this 
before leaving the assessment clinic. 
• All breast surgery for therapeutic or diagnostic purposes should be performed or supervised by a 
consultant surgeon with a special interest in breast disease. 
• Over 90% of diagnostic open surgical biopsies on impalpable lesions which subsequently prove benign 
should weigh less than 20g. 
• Routine pre-operative staging procedures in T1N0 breast cancer is not indicated. 
• Surgical procedures should follow agreed guidelines. 
 
Pathology (3,7,23) 
 
• It is essential for pathologists to distinguish cancer from benign conditions. 
• Pathologists need to report histological features of prognostic significance in order to ensure that 
patients are treated appropriately. 
• Pathology breast specimens should be reported by a consultant pathologist who has undertaken 
appropriate nationally recognised training and who participates in comparative audit. 
• It is usually necessary to use designated equipment in the pathology laboratory. 
• Where such equipment exists, its safety must be monitored. 
• A record should be kept of tissue taken from all types of specimens, which may be useful for research 
purposes. 
• It is important to record the histological features of cancers that are of prognostic significance (tumour 
size, grade, node status, vascular invasion and tumour type).  Careful clinical follow up is necessary to 
correlate the pathological features of tumours with clinical outcome. 
• Fine needle aspiration (FNA) cytology and wide bore needle biopsy are complementary techniques.  
Wide bore needle biopsies are increasingly being used in association with FNA cytology and may be 
highly effective where cytology is equivocal or where cytological expertise is not well developed. 
• When performed for the assessment of microcalcification they can be subjected to specimen 
radiography to ensure that the microcalcification is present in the core.  If benign calcification is found 
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in the core and this provides a satisfactory explanation of the calcification seen on the mammogram, 
diagnostic excision biopsy can be avoided 
• Evaluation of impalpable lesions and in-situ carcinomas requires specimen radiology to ensure that the 
specimen contains the radiological abnormality and to select the correct blocks of tissue for histological 
examination.  This technique adds significantly to the length of time required to examine such biopsy 
specimens.  Histological reporting of impalpable lesions should not be undertaken where specimen 
radiography cannot be performed. 
• If cytology or needle biopsy is negative in the face of strong clinical and radiological evidence of 
malignancy then they should be repeated and if still negative, an open biopsy performed. 
• Pathologists should not provide FNA cytopathology services unless they have sufficient experience and 
expertise. 
• A FNA report should be available within 24 hours of receipt of the slides or less, depending on the 
volume of patients going through the clinic. 
• A report should be available to the clinician within 24 hours of receipt of the core biopsy. 
The report of FNA cytology specimens should follow the following format : - 
• C1 = inadequate 
• C2 = benign 
• C3 = atypia probably benign 
• C4 = suspicious of malignancy 
• C5 = malignant 
Core biopsy specimens should similarly be classified B1 to B5. 
 
• Frozen section examination should generally be reserved for the unusual circumstances in which a 
definitive diagnosis cannot be made pre-operatively. 
• Frozen sections should not be done on impalpable lesions, as frozen section artefact may render accurate 
interpretatin of atypical ductal hyperplasia or ductal carcinoma in situ difficult to impossible. 
• Ductal carcinoma in situ (DICS) accounts for 5% of cancer in symptomatic women.  It may be difficult 
to distinguish DCIS from ductal hyperplasia and from minimally invasive cancers.  These distinctions 
require a great deal of expertise and experience in addition to extensive tissue sampling. 
 
Histopathology reports should include information on the following factors : - 
• The maximum diameter of the carcinoma should be measured in millimetres (mm) and the extent of 
intraductal and invasive disease recorded in the report. 
• The report should comment on the extent of disease and whether the tumour contains an extensive in 
situ component.  This is achieved by giving two measurements for invasive carcinomas where ductal 
(but no lobular) carcinoma in situ extends to more than 1 mm beyond the invasive component: 
a) the size of the invasive component: 
b) the size of the whole tumour. 
• Tumours identified as multicentric should be so reported. 
• The pathologist must report on the distance of surgical excision margins and this should be discussed at 
a multidisciplinary meeting.  An adequate margin may be defined as that margin which ensures a local 
recurrence rate in the conserved breast of less than 5% at 5 years. 
• Such a report cannot be given unless the surgeon clearly orientates and marks the specimen prior to 
delivery to the pathologist. 
• The Breast Unit must have a clear protocol for the handling of pathological specimens.  Subtyping of 
invasive and in situ cancers must use standard nomenclature as recommended by the European 
Guidelines for Quality Assurance. (23) 
• Histological grading of cancers must be undertaken using the method described by these pathology 
guidelines. (23) Results must be incorporated into the report. 
• Breast pathology specimens should be reported in a standard format. 
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• All lymph nodes recovered must be submitted for histological examination and the report should state 
the total number of lymph nodes found and the number of lymph nodes with metastatic disease. 
• Frozen sections should not be done on lymph nodes to examine them for metastatic disease because of 
the high risk of false negative results. 
• The presence or absence of lymphovascular invasion must be stated. 
• The use of immunohistochemical assay to determine oestrogen receptor status enables more detailed 
staging and grading of tumours.  Tumour receptor status (oestrogen receptor (ER) and progesterone 
receptor (PgR)) should be determined by using immunohistochemical techniques. 
 
Radiology (3,6,24) 
 
• The radiologist is an integral member of the multidisciplinary breast diagnostic team and has a major 
role to play in image guided diagnostic procedures. 
• These investigations should be performed by a properly trained radiographer, utilising high quality 
equipment.  They should be reported by appropriately trained radiologists with adequate experience. 
• Breast imaging should be carried out and reported by a radiologist experienced in breast imaging and 
who satisfies the agreed standards.  Radiologists must have skills in image guided diagnostic procedures 
as well as image interpretation skills. 
• The radiologist should be involved in decisions on the most appropriate imaging investigations. 
• Performance in mammography is directly related to expertise.  In order to achieve high preoperative 
diagnosis rates, the radiologist must have sufficient experience and expertise to perform these 
procedures effectively.  The radiologist must be properly trained and continuing medical education is an 
important requirement. 
• Feedback in the multidisciplinary setting is important.  Without obtaining outcome at pathology it is 
possible to make the same mistakes in interpretation despite a large number of mammograms reported. 
• A study of diagnostic accuracy found that radiologist who receive feedback on their own practice for all 
abnormal readings are more likely to recommend immediate workup for cases that turn out to be 
malignant than radiologists who do not receive regular feedback. (82)  Without obtaining feedback on the 
outcome of mammogram readings it is possible to continue to make the same mistakes in interpretation. 
(82) 
• It is desirable that a sufficient volume of image guided procedures should be undertaken to attain high 
pre-operative diagnosis rates. 
• Increased sensitivity for detection of small cancers has been demonstrated after attending dedicated 
teaching courses in mammography. 
• Reports of imaging examinations should include details of the size, size (mm), extent and nature of any 
abnormality, a description of any significant associated features with an opinion as to the most likely 
diagnosis. 
• Radiologists in dedicated symptomatic breast imaging must have access to high quality equipment 
(stereotactic biopsy equipment and ultrasound suitable for breast examination). 
 
Reasons and evidence 
 
• It is accepted that a multidisciplinary approach to breast cancer affords women the best therapeutic 
options when diagnosed with breast cancer. (3,4,5,25,26) 
• The cost of establishing high quality multidisciplinary breast clinics is largely offset by the reduction in 
bed occupancy and staffed theatre time. 
• The use of triple assessment can increase the speed and accuracy and reduce the cost of diagnosis when 
compared to selective use of component tests.  There is evidence and expert consensus that it 
substantially reduces the number of unnecessary operations performed both for benign disease and for 
breast cancer. (3,5,7) 
• High pre-operative diagnosis rates will 
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a) result in a very large reduction in the number of open benign and malignant surgical biopsies 
b) allow good surgical planning, giving an opportunity to counsel patients 
c) afford great benefit in terms of reduced morbidity associated with open surgical procedures and 
considerable reduction in the psychological trauma associated with multiple hospital admissions 
d) result in cost savings and reduce discomfort and inconvenience to the patient 
• There is strong evidence that triple assessment also provides a more accurate diagnosis than a reduced 
number of tests. (5,27,28,29,30,31,32)  If all three tests are positive the probability that the patient has breast 
cancer is over 99%.(32) 
• Definitive surgery for carcinoma can be decided preoperatively allowing treatment for any malignant 
lesions in a one-stage operation and avoiding the need for frozen sections. 
 
Results Clinic 
 
If a patient has had a core biopsy she will require a further visit to the clinic for results.  A patient who has a 
malignancy should never be given the result over the telephone.  The diagnosis and treatment should be 
discussed with the patient by the consultant surgeon.  A breast care nurse should be present as she has an 
important role to play in discussing the patient’s concerns and providing necessary information. 
• This visit should be within 5 working days of the diagnostic visit. 
• An appointment for the results clinic should be given before the woman leaves the diagnostic clinic. 
• The specialist breast care nurse should be available when women return to the results clinic. 
• The results should be given in the presence of a breast care nurse. 
• Breast care nurses provide advice, support and counselling to patients with breast cancer and their 
families. 
• The information should be given in a quiet area. 
• This is a crucial consultation.  It takes time for all options to be explained in detail. 
• Women who have indeterminate findings after the initial diagnostic clinic should have their cases 
discussed at a multidisciplinary meeting prior to receiving results. 
• At the time of the results clinic, women with a diagnosis of malignancy should be presented with 
therapeutic options available within an acceptable time frame. 
• Women requiring surgery for diagnostic or therapeutic purposes should be given a specific date for this 
before leaving the assessment clinic. 
 
Reasons and Evidence 
 
• Discussion a the multidisciplinary meeting will enable the clinicians to decide on the optimal treatment 
for the individual.  This will enable a more productive consultation with the woman to occur when the 
results clinic takes place. 
• Women have reduced long term morbidity if they understand the process. 
• While it is important for the consultation to take place quickly, the overriding consideration is the 
thoughtful planning of care for each individual patient. 
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Chapter 3 
Specialist Breast Unit 
 - Treatment and Follow up 
 
Treatment Principles 1 ,2, 3, 4) 
 
A number of principles should govern the treatment of breast cancer : 
• Treatment of breast cancer should be managed by staff with special training and expertise in breast 
disease. 
• Surgeons treating breast cancer should have undergone formal training in breast disease and should 
work in a Breast Team which has all the necessary facilities and expertise needed for a multidisciplinary 
approach. 
• Consultants in the Breast Team must have dedicated time for attendance at multidisciplinary meetings.  
In addition Breast Care Nurses and trainees in breast surgery must be in attendance at such meeting. 
• In order to collect accurate data preoperatively and to ensure efficiency in administration, data 
management and administrative clerical staff are required for a Breast Team. 
• The ratio of open surgical biopsies that prove benign to the total number of cancers diagnosed should be 
no more than 1:10. (This does not include operations for nipple discharge and previously diagnosed 
fibroadenomas). 
• More than 90% of patients with cancer should be admitted for operation within 3 weeks of the decision 
to operate. 
• Women with breast cancer should have the support of a Breast Care Nurse. 
• The Breast Care Nurse who is a member of the Breast Team should have established links with the ward 
nurses and other members of the Breast Team. 
• Follow-up arrangements must be defined by protocol and must involve the surgical team. 
• The Breast Team should be involved in biopsies, assessment and management of patients with locally 
recurrent and metastatic breast cancer.  Patients with metastatic breast cancer should remain under the 
care of the Breast Team. 
• All women diagnosed with breast cancer should have their management discussed with a surgeon 
trained in surgical oncology of the breast, a medical oncologist and a radiation oncologist. 
• Involvement in international clinical trials should be recommended, fostered and supported. 
 
Provision of Treatment 
 
Once a diagnosis of breast cancer is made, women should receive prompt planned treatment.  The CAWAC 
survey found that 39% of women with breast cancer were treated within one week of diagnosis, 28% were 
treated within 2 or 3 weeks and 25% waited one month or more after diagnosis for their treatment.  The 
survey found that 89% of the women with breast cancer had surgery, 44% had chemotherapy and 54% had 
radiotherapy in various combinations. 
 
The GP requires speedy, direct and focused communication from the Specialist Breast Unit. 
• Good communication is required both for patients with benign and malignant conditions but, because 
patients with cancer require a multidisciplinary approach, communication systems are required to be 
defined and explicit.  As the patient with breast cancer often needs the attention of several different 
speciality groups, it is therefore particularly important that the GP receives accurate, up-to-date and 
unambiguous information. 
• It is desirable that the GP be consulted about the pathway of treatment before it starts. 
• The GP should be involved in the physical and psychological rehabilitation of patients with breast 
cancer and in crucial decisions relating to the management of metastatic disease. 
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Mode of Treatment 
 
Surgery 
 
Surgery to the breast aims at excising all the disease to maximise chances of cure and local control of the 
disease together with the provision of accurate pathology staging and a satisfactory cosmetic result.  In 
deciding on which treatment is most suitable for each woman, it is necessary to take into account features of 
the tumour, and the status of the axillary nodes.  Pre-operative diagnosis will enable the clinician to discuss 
the options with the woman in advance.  The range of surgical options includes mastectomy and breast 
conserving surgery (wide local excision or lumpectomy).  Treatment for breast cancer has changed 
considerably over recent years.  An important change has been the shift from mastectomy, which was the 
standard treatment in the early eighties.  The move to breast-conservation surgery occurred when studies 
revealed that breast conservation followed by radiation therapy was a real alternative without compromising 
survival. 25,34 
 
Breast conserving surgery (followed by radiation therapy to the conserved breast) is the treatment of choice 
for unifocal invasive breast cancer provided that the disease can be excised with clear margins of a t least 
5mm around the tumour.  Rigorous histopathological assessment of the margins of the excised specimen is 
required.  Some patients who have undergone conservative resection for invasive breast cancer require 
further excision or completion mastectomy once the full histological report is available as the risk of local 
recurrence with the breast is unacceptably high if the resection margins are involved by tumour.  UK studies 
have found variation in the rates of breast conservation treatments.35,36,37   Not all patients are suitable for 
breast conservation surgery.  Mastectomy is indicated in situations where the disease is multifocal or in 
situations where radiotherapy is contra-indicated.  The possibility of breast reconstruction should be offered 
to all patients undergoing mastectomy. 
 
Surgery to the axilla is recommended to stage the disease, provide prognostic information. Plan further 
systemic therapy and to minimise local recurrence in the axilla.  Formal axillary dissection (Levels, I,II and 
III) provides the most accurate staging information on the axilla.  A relationship exists between the size of 
the tumour and the likelihood of the axillary lymph nodes being affected.  If a tumour is more than 5 cms in 
diameter, more than 60% of patients have invloved axillary lymph nodes whereas when the tumour is less 
than 0.5cm the nodes are affected in only 3% of cases.  Patients with uninvolved axillary lymph nodes do 
not benefit from axillary dissection and identification of such patients before the lymph nodes are 
completely excised would obviously be desirable.  Evaluation of the first lymph node that drains the tumour 
area (sentinel node biopsy) is under investigation in an attempt to avoid extensive surgery on an uninvolved 
axilla.  The ideal technique, the extent of the histopathological examination and the training required for 
accurate and reproducible results have yet to be determined.  For this reason the sentinel node method 
remains investigational and should be carried out only in the context of a promising method under 
evaluation.  Individual surgeons’ results must be audited before the sentinel node assessment becomes the 
only axillary intervention. 
 
Radiotherapy 
 
Radiotherapy uses high energy x-rays to destroy cancer cells while doing as little harm as possible to normal 
tissue.  Breast irradiation is clearly indicated after breast conserving surgery and, in anticipation of this 
treatment, the use of metallic clips around the breast cavity following removal of the tumour, is desirable.  
The tumour bed can then be seen on x-ray films allowing a radiation boost to the area if this is indicated.  
Radiotherapy to the chest will following mastectomy is also indicated in patients with a high risk of local 
recurrence.  Post-mastectomy radiation is considered for patients who, in spite of having adequate surgical 
treatment remain at a high risk of local recurrence e.g. patients with extensive axillary node metastases, 
lymphovascular permeation or close margins. 
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Systemic therapy 
 
The aim of systemic treatment is to treat undetectable cancer and improve survival.  Systemic therapies are 
highly cost effective in most women with early breast cancer. 38,39  Substantial reductions in recurrence and 
mortality in women with early breast cancer up to the age  of at least 70 years can be produced by the 
administration of adjuvant chemotherapy such as Cyclophosphamide, Methotrexate  and Flourouracil 
(CMF) or Anthracycline-based regimes.  Trials of different types, dosages and duration of adjuvant 
chemotherapy and endocrine therapies are underway and, where feasible, patients should be invited to 
participate in such studies.  Systemic adjuvant therapy should be considered for all patients except for those 
with a minimal or low risk of recurrent disease.  Included in this group would be all node-positive patients 
and node-negative patients with tumours which are oestrogen-receptor (ER) and progesterone-receptor 
(PgR) negative and those with other unfavourable histological or biological indices.  For node-negative 
patients at low risk who are also ER or PgR positive, Pamoxifen with or without chemotherapy is 
appropriate while for high risk node-negative patients who are ER and PgR positive, chemotherapy in 
addition to Tamoxifen are currently recommended.  For patients with involved lymph nodes chemotherapy 
is recommended with the addition of Tamoxifen in ER or PgR positive women. 
 
Requirements 
 
Surgery  3,23 
 
• All breast surgery for therapeutic or diagnostic purposes should be performed or supervised by a 
consultant surgeon experienced in and with a special interest in breast disease. 
• Surgeons should have the technical skills to support a full range of choices. 
• Unless clinical circumstances dictate otherwise, surgery should be carried out within no more than 14 
and preferably within 7 working days of confirming the diagnosis. 
• Breast surgery, the management of excised specimens and treatment decisions based on pathology and 
other prognostic information should follow locally written protocols based on the BASO guidelines. 
• In order to demonstrate adequacy of exclusion the entire surface of the biopsy should be painted with 
India Ink. 
• Surgeons should not slice the specimen or sample it before sending it for histopathological examination. 
• The pathologist should confirm that the margins of excised tissue are free of tumour cells. 
• Patients who are found to have positive margins should be offered re-excision or mastectomy. 
• The possible adverse effects and anticipated benefits of axillary sampling or clearance should be 
discussed with patients. 
• Breast reconstruction should be discussed with patients who are to undergo mastectomy and it should be 
available through either a plastic surgeon or a breast surgeon trained in the appropriate techniques and 
should be offered to all women in whom it is clinically indicated. 
• The breast care nurse should discuss with patients the fitting and supply of breast prostheses and suitable 
clothing.  A patient’s discharge should be planned to ensure that the necessary support facilities are 
available. 
 
Systemic therapies 4,5,41 
 
• Patients with invasive breast cancer should be offered adjuvant systemic therapy (hormone therapy 
and/or chemotherapy) if appropriate. 
• The choice of systemic therapy should be guided by protocols based on up-to-date best evidence. 
• Risk and benefits of the different options should be discussed with the patients. 
• Chemotherapy should be initiated and supervised by clinicians who are appropriately accredited and 
experienced and administered only by appropriately trained staff. 
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• Cytotoxic chemotherapy should be carried out in facilities that are properly equipped for the purpose. 
• Responsibility for the maintenance of safe procedures and standards of practice lies with the consultant 
concerned. 
• Consultant medical oncologists treating patients with breast cancer should be part of a multidisciplinary 
team and participate in team meetings. 
• There should be written protocols for the management of complications and side-effects. 
• When clinically appropriate, adjuvant therapy should begin within 15 working days of the decision to 
give adjuvant chemotherapy. 
• Urgent chemotherapy should start within 48 hours and ideally within 24 hours. 
• Patients receiving chemotherapy and their GPs should have access to emergency care, information and 
advice from oncology trained staff on a 24-hour basis. 
• They should be given written information on appropriate action for dealing with side-effects of 
chemotherapy. 
 
Radiotherapy (41) 
 
• There should be pathological confirmation of the diagnosis wherever possible. 
• All patients treated with radical intent should have an accurately documented tumour stage according to 
an internationally (usually TNM) accepted system. 
• The treatment intent should be clear: curative, adjuvant or palliative. 
• The first outpatient appointment should be within 2 weeks of the receipt of referral. 
• Local breast irradiation should be started as soon as possible after surgery 14 usually within 6 weeks 
except for patients in whom radiotherapy is preceded by chemotherapy. 
• Urgent radiotherapy should start within 24 hours. 
• Palliative radiotherapy should start within 2 weeks (ideally within 48 hours depending on symptom 
severity). 
• Radical radiotherapy should start within 4 weeks (ideally within 2 weeks). 
• Consultant radiotherapists treating patients with breast cancer should be part of a multidisciplinary team 
and participate in team meetings. 
• External beam radiotherapy should conform to the recommendation of the COIN radiotherapy Working 
Group (42) and where appropriate other European and international advisory bodies. 
• Each department must have a standard method of treatment plan normalisation and define a standard for 
treatment plan acceptability. 
• The option of radiotherapy should be discussed with patients before the primary treatment. 
• Women who undergo breast conservation should be advised to have postoperative breast irradiation 
mainly because its omission increases the risk of in-breast recurrence.14 
• Postmastectomy irradiation should be considered for patients who despite proper surgery and adjuvant 
systemic therapy are at high risk of local recurrence. 14 
 
Reasons and Evidence 
 
Surgery  4,5,14 
 
• Research had revealed that survival is equivalent between breast conserving surgery and radiation and 
mastectomy alone. 
• There is evidence that local recurrence is more probable when cancer cells from tumour margins are left 
behind after initial surgery, even after radiotherapy. 
• There is strong evidence from Randomised Controlled Trials (RCTs) that surgical margin status is a 
strong predictor of long term local recurrence rates, which can range from 5% to 20% at ten years when 
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breast conserving surgery is given with radiotherapy (43) and may reach 30% at five years if radiotherapy 
is not given.(44) 
• Individual surgeons must evaluate and audit their local recurrence rates. 
• The involvement of the axillary nodes is an important prognostic indicator.  Histopathological 
evaluation of the axilla is a useful tool for estimation of risk of relapse and staging of the axilla by 
sampling or clearance of lymph nodes allows appropriate management of clinical disease. 
• Axillary clearance is the most widely accepted surgical treatment for the axilla. 
• Surgical evaluation of the axilla can be performed with sentinel node technology, axillary sampling or 
axillary clearance.  These procedures should follow agreed national guidelines. 
• Axillary nodes can be positive even in very small cancers. 
• Node positive women should have axillary clearance or radiotherapy. 
• Greater morbidity is seen among women treated with radiotherapy.(45) 
• Axillary clearance may have therapeutic and prognostic advantages but there is an associated morbidity 
(lymphoedema and limitation of arm movement) in a small percentage of patients. 
• Axullary staging through the pathologic evaluation of the first lymph node that drains the tumour area 
(sentinel node biopsy) has been tested to avoid extensive surgery on a negative axilla.(46) 
• Sentinel node technology is an emerging technique.  It has potential advantages over traditional staging 
but it needs to be assessed in conjunction with standard techniques before being adopted as the only 
axillary staging.  This method remains investigational.  Individual surgeons need to carefully collect 
their data in order to verify results. 
• It is unclear whether patients with non-palpable axillary lymph nodes but with microscopic evidence of 
metastatic involvement benefit from surgical removal of these lymph nodes. 
 
Radiotherapy 4 
 
• Radiotherapy has been shown to reduce recurrence rates after surgery for primary breast cancer.  
• Adjuvant radiation therapy reduces isolated local recurrence rates by 67%. (47) The percentage of 
patients receiving radiation therapy following breast conservation surgery range from 12% to 75%  (48, 
49) and of adjuvant systemic therapy form 0 to 56% (48,50).  These variations may affect survival. (51) 
• Complications such as nerve and skin damage may offset the benefits in some women.  The 
complication rate may be minimised by guidelines on good practice. 
• Past evidence suggest that addition of radiotherapy to mastectomy does not affect overall mortality.(40)  
However, recent research indicates that some patients at very high risk of local recurrence might benefit 
from local and regional post operative radiation therapy. (52,53) 
• Radiotherapy to the axilla should not normally be given after surgical clearance of the axilla. 
• Radiotherapy has an important role in the management of symptoms associated with metastatic disease. 
• In symptomatic metastatic disease, radiotherapy can help to control pain and symptoms and reduce 
disability. 
• There is evidence of beneficial effects of radiotherapy in pain control in bone metastases (5,54,55) 
• neurological symptoms and function in brain metastases. (5,56) 
 
Systemic therapy 5,14 
 
• Starting chemotherapy immediately after diagnosis aims to influence tumour growth, avoid the 
development of resistance, reduce the size of positive axillary nodes an/or the size of the tumour and 
improve the control of local and systemic disease.(14) 
• Preoperative chemotherapy has been shown to be safe, yielding similar results in terms of disease-free 
survival and overall survival compared to the same regimen used following surgery. .(14) 
• Patients who receive preoperative chemotherapy are more likely to be candidates for breast conservation 
surgery. .(14,57) 
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• Clinical and pathological response to primary chemotherapy is associated with prolonged disease-free 
survival. .(14) 
• Post-surgical adjuvant therapy for early stage breast cancer is known to improve health outcome. 
• The effect is greater in younger women. 
• The survival benefit of an initial course of polychemotherapy increases with time.  The benefits are 
greater for node positive women. 
• Most trials involve CMF, usually for about 12 months but there is no evidence of differences in survival 
rates between CMF and other multiple agent regimens.  There is no evidence that shorter treatment 
regimens are less effective than longer courses of treatment. .(40) 
• Tamoxifen is an important component of treatment for women with tumours that express steriod 
hormone receptor. 
• Treatment with Tamoxifen for 5 years or more has been found to reduce the risk of death by 38% and is 
more effective than treatment for one year.  There is no evidence that higher doses are more effective 
than the standard dose of 20mg. 
• There appears to be no justification for withholding Tamoxifen from older women. 
• Combined chemotherapy and Tamoxifen is associated with better outcome compared to Tamoxifen 
alone. 
• The optimal way to administer Tamoxifen (either concomitant with or sequential to chemotherapy) is 
unsettled. 
• Ovarian ablation can have beneficial effects in women with primary breast cancer. .(5,58) 
• There is evidence that ovarian ablations as effective as chemotherapy for pre-menopausal women. .(14,40) 
• The occurrence and severity of long-term side-effects are still significant issues when this treatment is 
given to younger women. .(14) 
 
Support Services 
 
Women may need help and support during the difficult time of their diagnosis and treatment.  Breast Units 
should be able to offer specialist advice regarding 
•  the availability of wigs and prostheses an other supports such as 
• social work services, 
• psychology etc. 
 
Provision of information is an important element of the care of women with breast cancer.  The CAWAC 
survey found that 40% of women still knew little about cancer after diagnosis and treatment. .(19) 
 
The Breast Unit should also liaise with voluntary organisations who have much to offer in recovery 
programmes and specialist palliative care.  The Breast Unit should offer support and continuing advice 
regarding new medical developments to the voluntary organisations that work so diligently in the field. 
 
Follow up 
 
Arrangements for follow up, at present, are very variable.  Many women are called back for frequent follow-
up which is demanding on the patient and clinic time and resources.  Agreed follow-up procedures that 
would include the GP should be considered. 
 
Requirements 
 
• Regular mammography is important to detect local recurrence or a second primary cancer in the other 
breast. 
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• All women who have been treated with breast conservation for breast cancer should undergo 
mammography yearly during the first 5 years after surgery and every two years thereafter. 
• Some women who have had mastectomy should have biannual mammography on the contralateral 
breast. 
• Most recurrences are symptomatic when detected .(5,59) and are most often detected by the woman herself 
between consultations.  Highly intensive follow-up of women who have been treated for primary breast 
cancer should not be routinely offered by the Breast Unit. 
• In view of the lack of evidence of benefit from routine follow up (other than mammography), the 
intensity and frequency of routine follow up by breast specialists should be re-evaluated.  This could 
only be done in co-operation with GPs and with the facility for speedy access to advice and re-referral 
where necessary. 
• GPs should be involved in developing arrangement for follow-up when routine follow-up at the Breast 
Unit is to be discontinued or reduced. 
• They will require good information on any new arrangements that are put in place, protocols regarding 
management and clear access to advice and patient review when required. 
• The GPs may require training in relevant aspects of breast cancer. 
• Individual surgeons must evaluate and audit their local recurrence rates. 
 
Reasons and Evidence 
 
• Patients value continuing relationships with a single provider whether it be a specialist of GP. .(14) 
• Ongoing care by trained GPs and access to a breast care nurse (61) will be convenient for the patient and 
will reduce the demand on the time and resources of the Breast Care Unit. (62) 
• Women wish to be fully informed and to participate in decisions regarding follow-up care. 
• They need to know how to access care when necessary. 
• They benefit from access to the breast care nurse for at least a year after surgery. (61) 
• Routine tests to detect metastatic disease are not necessary because they do not improve quality of life or 
survival. (5,59) 
• Patients followed up by their GP experience the same quality of life as those cared for by specialist 
clinics. (63) 
 
 
Metastatic Disease 
 
Women who have been treated for breast cancer my develop recurrence of the primary cancer or metastatic 
disease.  They are also at higher risk of developing a second primary disease.  To a large extend in breast 
cancer metastatic disease means metastatic bone disease, which is associated with a high level of borbidity 
and reduced quality of life.  The incidence of bone metastases is higher with steroid receptor positive 
tumours and those that are well-differentiated. (64,65)  Patients with bone metastases can present to a number 
of different specialities.  Their successful management requires a co-ordinated approach by clinicians with a 
special interest in metastatic bone disease.  At an appropriate stage in their care, patients with metastatic 
disease should be followed up at clinics dedicated to this group.  Indications for referral to this clinic will be 
agreed by surgeons, orthopaedic surgeons, oncologists and palliative care physicians. 
 
Most women with bone metastases will present with pain.  Initial presentation is often to the GP.  The 
degree of investigation required will depend on the level of clinical suspicion. 
• GPs should only undertake initial management if clinical suspicion is minimal (pain has known 
cause,resolving well at 2-3 weeks from onset) or low (probable cause of pain know, showing good 
resolution over 4-6 weeks). 
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• Where clinical suspicion is moderate (pain has no clear cause, persisting but not progressive) or high 
(pain has no identifiable cause, night pain, severe, and/or progressive, patients with any neurological 
symptoms or signs), GP should refer back to the breast clinic. 
• There is no role for routine skeletal survey or bone scanning of asymptomatic women with a history of 
breast cancer. (67,68,69) 
• Routine CT scanning is not considered to have a role in diagnosis. (26) 
• If plain X-ray and skeletal scintigraphy are negative but there continues to be a high level of suspicion 
then the investigation of choice is MRI scan. (26)  If MRI scan is not an option then skeletal scintigraphy 
should be repeated in 2-3 months.  Where there are X-ray abnormalities of uncertain significance bone 
biopsy should be considered particularly when other metastatic screening tests are negative or equivocal. 
• All patients with confirmed solitary or multiple metastases should receiver full clinical assessment and 
full set of staging investigations before treatment is planned. 
• Staging investigations to be completed within 10 working days of request and follow up clinic 
appointment within 1 week of completion. 
• Many breast cancer specialists believe that the use of chemotherapy can prolong  life in some patients. (5) 
• A wide variety of chemotherapeutic and hormonal agents are used in metastatic disease.  There is no 
evidence that any particular regimen is superior. (5) 
• In the absence of RCTs it is impossible to estimate the overall effects of treatment on quality and length 
of life. (5) 
• There is evidence that polychemotherapy produces a greater decrease in mortality over three year follow 
up than single agent therapy without substantial increase in toxicity. (5) 
 
Requirements 
 
• The Breast Unit should make available details of access to the clinic and the Unit should educate GPs in 
the management of women with skeletal pain and a history of breast cancer. 
• 90% of women referred back to the Breast Unit with bone pain to be seen within 10 working days 
receipt of referral and 90% to have had all their investigations completed within 10 working days. 
• All changes in diagnosis and management should be communicated to the GP promptly.  The clinic 
consultant, palliative care nurse, orthopaedic surgeon and consultant surgeon. 
• Guidelines are required. 
• Dedicated orthopaedic surgeon linked to each Breast Unit with sessional time should attend 
multidisciplinary meeting where these patients are discussed.  Breast care team should have regular 
participation of an identified orthopaedic surgeon with an interest in metastatic disease and a radiologist 
with an interest in metastatic disease. (26) 
• Orthopaedic surgeon should be responsible for liaising with tertiary specialist colleagues as necessary 
and ensure that a rota and contact numbers are always available to colleagues on the breast care team. 
(26) 
• Breast care team should provide clear details of rapid access to appropriate assessment to all members of 
the team, to GPs, to breast care nurses, to patients and to local staff in related disciplines. (26) 
• The multidisciplinary team should record the management pathway, which will vary from patient to 
patient. 
 
Reasons and Evidence 
 
• Improvements in the understanding and management of metastatic bone disease offers the hope of better 
therapeutic options and it is important that they are referred for expert treatment as early as possible. 
• Guidelines will set high standards of care and will bring about a great alleviation of the effects of bone 
metastases in many women. (26) 
• Early detection of metastatic disease in asymptomatic women by imaging and biochemistry does not 
improve survival. (67,68) 
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• Tumour markers may be of use for diagnostic purposes as long as the correct cut-off points are used to 
interpret the results. (26)  This is particularly important in confirming the diagnosis of metastatic disease 
in the presence of  suspicious or equivocal imaging investigations. (70) 
• It is unusual to have positive findings on CT scan if skeletal scintigraphy is negative. (26) 
• A recent review of women with bone metastases in breast cancer found that an orthopaedic surgeon was 
only consulted in 50% of occasions when their input would have been appropriate. (66) 
• Orthopaedic surgeons can make an invaluable contribution to the assessment of patients in whom the 
distinction between mechanical and non-mechanical pain is difficult. (26) The surgical techniques used in 
metastatic bone disease differ from those used in routine orthopaedic practice. 
 
Specialist Palliative Care 
 
Women with breast cancer should have access to palliative care at an appropriate time.  Depending on the 
stage of the illness they may require physical, phychological, social or spiritual support.  Close liaison 
between the Breast Unit and the palliative care specialists is essential.  Requirements for Specialist 
Palliative Care are outlined in detail in the report ‘‘Development of Palliative Care Services’’. (71) 
 
Requirements 
 
There should be close links at an early stage between the specialist palliative care team and hospital 
diagnostic team.  The specialist palliative care team prefers to meet the patient at an early stage.  Patients 
should be acquainted at an appropriate stage in their disease with the specialist palliative care team.  At 
various stages in the patient’s illness she may require the support of social services for care and advice. 
 
Reasons and evidence 
 
• There is evidence that pain management is often sub-optimal. (72,73) 
• Pain can be controlled through appropriate treatments. 
• Multi-professional specialist palliative care teams provide better quality of care. 
• Conventional care alone is likely to be inadequate. 
• The breast care team should be supported by a specialist palliative care team.  Indication for referral to 
the specialist palliative care team should be agreed by breast surgeons, medical oncologists and the 
palliative care physician. 
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CHAPTER 4 
Current Service Provision 
 
Introduction 
 
Information regarding the current service provision was gathered through questionnaires completed by the 
Regional Cancer Directors and visits to hospitals in each Health Board region, which were organised by the 
Regional Cancer Directors.  Appendix 2 shows a list of hospitals visited.  Confidential data provided by the 
National Cancer Registry (NCR) relating to breast cancers diagnosed in each Health Board region was 
examined.  Some patients are diagnosed in hospitals outside their own Health Board.  The Regional Cancer 
Directors also provided some data regarding the number of breast cancers diagnosed in hospitals in their 
regions.  One of the difficulties encountered was the lack of systematic data collection throughout the 
country.  It was difficult to obtain full details of the symptomatic breast disease activity at all hospitals as 
this information is not always routinely recorded.  However, it is estimated that for every one case of breast 
cancer detected, 17 to 20 patients will require assessment. 
 
It is not possible to obtain a clear picture of the organisation of breast services, detailed throughput for 
symptomatic breast services, treatments or outcomes.  UK data revealed that their cancer survival rates 
compare unfavourably with those of other countries.  They made changes to their services based on best 
practice and achieved an improvement in outcome.  It would be useful if there were data available to judge 
the performance of breast services in Ireland.  From the information obtainable, it appears that the 
management of breast cancer differs between surgeons and between hospitals as was found in studies from 
other countries.  Few hospitals diagnose 100 cases per year.  Surgery for breast cancer is performed in most 
general hospitals by general surgeons.  In some cases particular surgeons have expressed a special interest in 
breast disease. 
 
In recognition of the evidence available in the literature, there has been a move recently to establish breast 
clinics.  Creative solutions were found for logistic difficulties.  For example, clinicians form other hospitals 
were brought in to provide expertise such as surgery or medical oncology and services such as 
mammography and pathology were contracted from neighbouring hospitals. 
 
General Findings 
 
The level of service provision varies throughout the country.  The main findings are summarised below : 
• Variable practices in the type of surgery being performed 
• High rate of open biopsy for benign disease 
• High rate of open biopsy for malignant disease 
• High rate of benign to malignant biopsies 
• Lack of pre-operative diagnosis 
• Lack of preoperative treatment planning 
• No surgical training programme for breast disease exists in the country 
• Major issues in surgery 
a) large variation in the type of surgery  being carried out on the breast 
b) lack of accuracy or protocols in assessment of tumour margins 
c) variation in the surgical operations on the axilla 
• Unequal access to pathology services with large variation in the detail of reports by pathologists for 
example 
a) variable accuracy of pathology assessment of tumour margins, 
b) variation in the detail of reporting numbers of axillary lymph nodes and 
c) lack of uniform proformas and standard protocols 
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• Unequal access to ultrasound facilities 
• Mammography with no dedicated processing 
• Variable and unstructured GP access to mammography 
• Variable and unstructured GP referral and follow-up. 
• Radiotherapy/oncology 
d) access to adjuvant therapy difficult 
e) where it exists it is sub-optimal 
f) consultant availability very variable 
• Lack of Breast Clinics; women seen as part of general surgical clinic 
• Multidisciplinary meetings are uncommon. 
• Clinical trial uptake minimal; number of patients recruited into clinical trials is low 
• No organisation in management of metastatic breast cancer. 
• Follow-up variable 
• Data not collected to enable evaluation of quality of care. 
 
In examining the structure, a number of disadvantages were noted which might militate against good 
practice. 
• Lack of resources 
• Inability to provide Triple Assessment in many places because the structure is not there. 
• Lack of radiotherapy, oncology services etc. 
• Insufficient theatre capacity in some hospital to ensure protected time for breast cancer patients 
• Geographic difficulties 
• Transport difficulties 
• Political difficulties 
• Currently many centres do not have the volume of patients to maintain optimum expertise. 
• May be recruitment difficulties in some areas e.g. radiologists, cytotechnicians 
• Will take time to establish specialist Breast Units and regional oncology services. 
 
However, there are many strengths within the system.  There have been infrastructural developments that if 
improved will provide a better service. 
• Commitment, skills 
• Some degree of sub-specialisation has developed 
• Dedicated breast clinics in some hospitals 
• Multidisciplinary meeting in some hospitals 
• Triple Assessment in some hospitals 
• Many have already started to move towards a quality service and identified some of the difficulties. 
• Not starting form scratch but building on strong foundation 
 
Mammography 
 
• There is an enormous amount of opportunistic screening taking place that is not being formally 
evaluated.  It may not be beneficial. 
• Some hospitals provide screening mammography for GPs; others channel all referrals through the 
surgeon who will decide on the management. 
• Hospitals have seen an increase in the referrals from GPs, some of who believe that a national breast 
screening programme is already available nationwide. 
• Women are increasingly presenting to GPs requesting mammography and GPs in turn are referring them 
to the hospital for the service. 
• Part of the increase is due to an increasing awareness among women and also a mistaken impression that 
the NBSP is already in operation on a countrywide basis. 
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• Due to a lack of access to diagnostic breast clinics in many areas many GPs find themselves with no 
option other than to send women for mammography. 
• Public concern about breast cancer has led charitable organisations to raise funds to purchase 
mammography equipment in the belief that this is the only requirement for diagnosis of breast cancer. 
 
Surgery 
 
• Many surgeons throughout the country undertake breast surgery.  The number of breast cancer patients 
seen by them varies. 
• Based on figures provided by the NCR, only one hospital diagnosed more than 100 new cases of breast 
cancer per year and seven public hospitals diagnosed more than 50 cases in 1996. 
• There are a considerable number of open diagnostic malignant and benign biopsies. 
 
Pathology 
 
• Facilities for pathology are variable. 
• Some centres have access to histology and analysis of core biopsies. 
• There were a few centres providing FNA cytology but this is relatively rare. 
• There is a shortage of cytotechnicians. 
 
Oncology 
 
• Information regarding adjuvant chemotherapy was scanty. 
• There have been a lot of new appointments made recently. 
• It is vital that protocols and guidelines should dictate management. 
 
From the review, it was clearly apparent that change is required.  Women throughout the country should 
have access to a uniform standard of care.  It would not be possible to provide high quality services in every 
hospital but the aim would be that all women would have access to a Specialised Breast Unit. 
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CHAPTER 5 
The Recommendations 
 
Recommendations 
 
Based on the requirements for good care, the following recommendations are proposed. 
• Specialist Breast Units should be established throughout the country.  These units should be fully staffed 
and resourced in order to deal with patients with breast disease. 
• The Specialist Breast Unit should be based on a population of 250,000 to 300,000 from which it is 
expected that there will be, at a minimum, 100 new primary breast cancers per annum. 
• There should be at least two surgeons attached to the Breast Unit.  The lead surgeon should normally 
have a minimum of six fixed session and other surgeons attending with a special interest in breast 
disease should have a minimum of at least three sessions in the Breast Unit, covering GP referral clinics, 
follow up clinics, breast operating lists, attendance at multidisciplinary meetings and weekly combined 
breast clinics. 
• Requirements for the training of a surgeon with a special interest in breast disease and the arrangements 
needed or a designated training centre have been submitted as recommendations to the Royal College of 
Surgeons in Ireland. 
• Two nominated radiologists trained and with continuing experience in breast disease.  They must be 
available for reading mammograms and carrying out ultrasound and stereotactic investigations required 
at new referrals clinics.  They must be available to report mammograms on all cases arising from the 
breast diagnostic work of the unit and to attend the multidisciplinary meetings and audit meetings.  In 
some areas it may not be feasible to have two radiologists based in the hospital and special arrangements 
may be necessary. Radiologists should have the opportunity to attend specialist training courses similar 
to training courses available to radiologists working in the UK. 
• Two pathologists will be responsible for all breast pathology and cytology.  They must have dedicated 
session to attend multidiscplinary breast meetings and audit meetings. 
• At least two breast care nurses available per 100 cancer patients to counsel and offer practical advice 
and emotional support to newly diagnosed patients, discuss treatment options with them and provide a 
prosthetic service. 
• The medical oncologist and radiotherapist must arrange the appropriate delivery of radiotherapy and 
chemotherapy.  They should hold joint clinics with other members of the breast care team and must take 
part in multdisciplinary and audit meetings.  While they may be based at another hospital they should 
have dedicated sessions at the Breast Unit. 
• Breast diagnostic radiographers with necessary training and expertise in mammography.  They must 
hold a certificate of competence in mammography. 
• Clerical support including two full-time secretaries of high grade and an administrative office to 
organise the clinic and a data manager in each unit. 
• Each medical discipline (surgery, medical oncology, radiation oncology, orthopaedic surgery, and 
specialist palliative care) should have written protocols of management of patients with breast cancer. 
• Management of all patients with breast cancer should be discussed at a multidisciplinary meeting. 
• There must be swift effective communication between the Specialist Breast Unit and the GP.  There 
should be minimal delay between referral of a woman with a lump form the GP and an outpatient 
appointment and between first consultation and communication of the diagnosis with the patient and the 
GP. 
• Patients should be recruited into clinical trials where feasible. 
• Modern methods of audit and monitoring of outcomes must be put in place.  This requires effective data 
management.  It requires both routine audit and the basic infrastructure for collection of data concerning 
patients, their disease, treatment and outcomes, and systematic reporting and recording of pathology 
data. 
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• A Breast Unit Annual Report, containing data according to protocol from each Breast Unit should be 
prepared by a designated lead person in each Unit. 
• All Units should be interlinked so that identified information is collected from each centre in such a way 
as to be amenable to comparison among centres and to external audit. 
• All Breast Units should combine annually for an audit/outcome meeting to monitor and verify that audit 
standards are being reached and maintained. 
• A national Annual Report should be produced. 
• Annual Quality Assurance meetings among all Units are necessary in the same way as in screening 
programme. 
• Individual sub-speciality audit should be performed.  Each group should analyse its own performance 
indicators and agree protocols. 
• A national executive multidisciplinary committee, whose function is to analyse the activities of the 
Breast Units, should meet at least annually. 
• A centralised Quality Assurance Office should be established and staffed appropriately with a data 
collection and evaluation manager supported by clerical staff.  It should 
a) collect data from the regional Breast Units, 
b) co-ordinate and organise the annual audit meetings and  
c) produce a National Annual Report. 
• A Reference Unit should be established.  The function of the Reference Unit would 
a) act as a facilitator and advisor to other Units, particularly in unusual or complex cases and  
b) promote research activity among Units 
c) be responsible for additional specialist training 
d) house the Quality Assurance Office 
• A Breast Cancer Multidisciplinary Advisory Group should be established to 
a) advise the Minister for Health and Children on the functioning of the Breast Units 
b) make recommendations concerning the quality of care in each unit 
c) keep under review developments in research in the area of breast cancer 
d) provide advice on service changes that may be required as a result of research developments 
e) provide advice on new or unusual interventional procedures such as vacuum-assisted biopsy 
techniques.  These techniques are being developed in screening services.  Resources should be used 
in the most efficient manner and they should be centralised as much as possible. 
• Organisation of the Breast Unit should include ensuring that transport arrangements are in place to 
facilitate women residing in areas that may pose logistic difficulties in travelling to the Unit.  This could 
include consideration of initiatives such as (11) 
a) van/bus assistance services, 
b) taxi services at reduced fares, 
c) financial support to individuals who provide informal transportation assistance to patients 
d) voluntary transport assistance to women via Cancer support groups. 
• Each health board should examine the geography, road system and population distribution of their own 
region in order to identify subgroups of women who may have particular difficulties with transport that 
would deter them from availing of the services provided by the Breast Unit. 
• While it may be possible for follow-up treatment to be carried out in hospitals other than the Breast 
Unit, all surgery and diagnostic procedures must be undertaken at the Breast Unit. 
• If difficulties are encountered in implementing these recommendations the National Cancer Forum 
should be consulted and changes must not be made to the recommendations without approval of the 
National Cancer Forum. 
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Introduction 
 
There are some long-established breast clinics throughout the country and over the last few years a 
significant number of new clinics have been established.  Many do not have the population base to enable 
sufficient volume of patients and concentration of expertise.  During the visits, staff in many of the newly 
established smaller clinics expressed concern about the lack of volume and the medico-legal consequences.   
In formulating the recommendations note was taken of the breast clinics that were long established.  
Equipment has to be used to the maximum in order to be cost effective.  No professional should be expected 
to provide treatment without state of the art equipment and facilities.  However, it is important to keep in 
mind the efficient use of taxpayers’ money in the provision of a cost-effective service in a health service that 
has a limited budget.  Each Unit will need to be fully funded.  In many of the places the facilities are already 
in place and will not need to be set up from scratch.  A needs assessment should be undertaken in each 
location.  This formal assessment should be undertaken in each centre by the health board in the first 
instance and agreed with the Department of Health & Children. 
Issues that need to be considered include ensuring that each professional has enough sessions to undertake 
the work in the Unit, that they have sufficient cover when they are on holiday, and ensuring that their 
routine work is covered at their base hospital when the particular professionals are working at the Breast 
Unit. 
 
The Issues 
 
• The decision regarding where to locate the Breast Unit in each Health Board is difficult. 
• The factors to be considered include geography, population, custom and established pattern of health 
service use, plans for development under the National Cancer Strategy and skills and expertise and the 
facilities that are already in place. 
• It is the view of the sub-group that professionals with an expressed interest in breast disease should be 
accommodated in their wish to continue to provide a service through the Specialist Breast Units. 
• Creative solutions may be required to enable professionals from hospitals that are not part of the Breast 
Unit to participate in the service provision. 
• Breast cancer does not usually require high dependency care and so can be sited in Specialist Breast 
Units that may not necessarily have high dependency facilities. 
• Some women may require treatment in a dedicated oncology centre. 
• Specialist staff can travel to designated Breast Units to deliver the service and so utilise their expertise. 
• Given the infrastructure required and the number of new breast cancer cases per year in each health 
board, the number of hospitals where Specialist Breast Units can be established is limited. 
• As can be seen from the map of Ireland Appendix 3, apart from the larger SHB and EHB, each health 
board has a population that would be expected to produce 100 new cases of breast cancer per year.  A 
case could be made for siting one specialist Breast Unit in each of these health boards. 
• However, this is an overestimate of the breast cancers that would be seen at a Breast Unit, as some 
patients will attend a private facilities or attend centres outside their own health board area.  In the case 
of health board that are included in the screening programme, those cancers that are diagnosed by the 
NBSP will be treated by the NBSP rather than the Specialist Breast Unit. 
• Despite limiting it to one Breast Unit per health board, the desired throughput for the Units will still only 
be marginally achieved. 
• A large number of women are treated outside the public health service in the private sector.  It is 
essential that providers of private health insurance are aware of the evidence supporting the 
establishment of Specialist Breast Units.  The private sector should be encouraged to follow the same 
guidelines and principles to ensure the same standard of care for all women. 
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Geography/Population 
 
In some Health Board areas there are regions with large geographical distances but with small population 
bases.  In some areas, women may have difficulties in getting from home to a particular hospital because of 
the distances that need to be travelled or because of the time it takes to get there due to public transport 
arrangements.  Travelling to clinics may be a source of great expense.  There is a fear that difficulties in 
travelling to the Breast Unit may result in some women (particularly in those with additional social and 
economic barriers) failing to attend for appointments.  There has not been in depth examination of this issue 
in the literature.  Most studies focus on the transportation barriers to screening mammography and 
prevention services.  For example: 
• In the Canadian National Breast Screening study only 5% of subjects listed excessive distance and 
travelling time as disincentives for screening. (74) 
• In Northern Ireland no relation was found between screening compliance and distance from mobile 
screening units, and few (4%) women expressed a preference for more accessible clinics. (75) 
With any study, it is important that the distance the women surveyed had to travel be taken into account.  
Those that have short distances to travel will not perceive transport and distance to be a barrier.  Also, many 
studies conduct their surveys on people who are attending the clinic.  The people who do not attend due to 
transport difficulties may not form part of the survey and their views are therefore not represented.  For 
example: 
• In the USA, a study in Northern Michigan, where only 26% of woman lived 20 miles or more from a 
mammography unit, found that most women did not consider lack of transport or distance to travel to be 
a problem in obtaining a mammogram 
• But in Southern Michigan, where 64% of the women lived 20 miles or more from a mammography unit, 
24% of women surveyed found transportation and distance to be a difficulty. (76) 
 
International studies indicate that few women use public transport to attend breast services (screening or 
symptomatic) or cancer treatment services. (11,20) The preliminary findings of Women’s Health Council 
study indicate that only a small percentage of women attending symptomatic breast services use public 
transport.  This may be partly because many of them see public transportation as a difficulty. (8)  The 
completed study may shed some more light in this issue. 
 
The majority of women who have benign breast disease will only require one visit to the Breast Unit but 
transportation is an important issue for patients with cancer who have to make many journeys for 
chemotherapy and/or radiotherapy. (11) The longer distances travelled result in higher personal costs to the 
patient and minority groups are more likely to be in need of assistance. (11) 
 
Currently in Ireland, 60% of women can get to their treatment centre within one hour, 23% are between one 
and three hours away and 7% travel over three hours for treatment. (19) It would not be feasible to provide a 
full Specialist Breast Unit to cater for a small number of women who have transport difficulties.  It would be 
more cost-effective to put in place suitable method to bring them to the Breast Unit and the literature shows 
improved survival for women who attend a high volume Specialist Breast Unit. 
 
Implementation of the report must include transport provision.  This may entail an organised transport 
service to the Breast Unit from the more inaccessible areas.  Careful deliberation will be required to ensure 
that the difficulty some women may have with travel is dealt with effectively.  Transport could be provided 
through the health board.  This could entail (11) 
• Van/bus assistance services 
• Taxi services at reduced fares 
• Financial support to individuals who provide informal transportation assistance to patients, or  
• Voluntary transport assistance to women via cancer support groups. 
 
 44
Each Health Board should examine the geography, road system and population distribution of its own 
region in order to identify subgroups of women who may have particular difficulties with transport that 
would deter them from availing of the services provided by the Breast Unit.  It is worth noting that: 
• The majority of people either have their own cars or have access to a car. 
• Most women will only require one diagnostic visit so they will have to travel only on one occasion. 
• If they have triple assessment, then the majority of women will have only one visit.  Even if they have a 
core biopsy, an appropriate professional from the Unit can telephone the women with benign result and 
inform them that they do not need to return. 
• The vast majority will not have breast cancer and will not be required to return to the clinic. 
• While it may be possible for follow-up treatment to be carried out in hospitals other that the Breast Unit, 
all surgery and diagnostic procedures must be undertaken at the Breast Unit. 
• A difficulty will occur with the provision of radiotherapy and possibly chemotherapy.  This problem will 
arise no matter where the diagnosis is made.  Provision of radiotherapy and chemotherapy does not 
necessarily need to take place in the Breast Unit but may be provided in a hospital closer to the patient’s 
home if the facility is available there and the consultant providing the treatment is part of the Breast 
Care Team. 
• Women are willing to travel if there is a better outcome. 
 
Network-one unit on two sites 
 
The option of providing a network encompassing ‘‘one virtual Unit’’ on a number of sites has been 
suggested by some people.  However, it would lead to a dilution of expertise and expensive equipment 
would be underutilised.  If there is an insufficient volume of patients, multidisciplinary meeting do not 
happen.  A sufficient volume of patients is needed to justify multidisciplinary meetings and clinics.  There is 
great benefit to be derived from a team of people working together routinely. 
 
Planning of services 
 
Service planning has tended to be ad hoc in the past.  This has led to charitable organisations around the 
country purchasing equipment in the belief that it will be of benefit to women.  This equipment is often 
purchased without revenue support and frequently without the required numbers of patients to guarantee the 
maintenance of expertise.  It does not always fit with the health board’s broad plan for services in the 
region.  The reality is that management of breast disease is multidisciplinary and requires co-ordinated 
planning and implementation.  Purchasing individual items of equipment is inadvisable and does not 
contribute to good quality care. 
 
Location of units 
 
Locating Breast Units within Health Boards has the following advantages: 
• It is the established administrative structure of the health services. 
• There are administrative and financial arrangements in place. 
• Tradition and practice. 
• Health Boards, broadly speaking, largely conform to the population base required to establish Breast 
Units. 
• Referral linkages are already established with primary care and between hospitals on a Health Board 
basis. 
• There is the option of transcending Health Boards where necessary.  Transgressing Health Board 
boundaries would be administratively difficult but it may be necessary in some situations.  This would 
be in keeping with the principles of the National Cancer Strategy, which recognises that it is necessary 
for some specialist services such as radiotherapy to be provided on a Regional basis. 
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Location of Units 
 
South Eastern Health Board 
 
The population base justifies one unit.  The South  Eastern Health Board has ratified the decision to 
centralise services in Waterford.  A significant amount of forward planning at an administrative and 
organisational level has been carried out within the region.  A formal plan for the region has been presented.  
This plan is in keeping with the guiding principles.  It is recognised that other acute hospitals in the area 
have surgeons and other professionals who have an interest in breast disease who could travel to the centre 
to carry out breast work there.  Such an arrangement would neatly combine the maximum possible use of 
resources and personnel while maintaining job satisfaction and expert individual attention.  Additional posts 
and sessional commitments will be required to allow for surgical sub-specialisation. 
 
Southern Health Board 
 
The population in the Southern Health Board is large enough to support two units.  Based on the population, 
it seems appropriate to have two centres in Cork City as no centre outside the city has sufficient population 
to justify a full unit. 
 
The South Infirmary has the largest number of cancers seen each year.  It has clinical and radiological 
expertise developed over 15 years.  It provides an excellent, integrated, efficient and patient-oriented 
service, despite the fact that it does not have on-site pathology.  This would appear to be the appropriate site 
to base a Breast Unit.  Cork University Hospital (CUH) has established a breast clinic recently.  They do not 
have on-site mammography.  One consultant surgeon at the hospital undertakes breast surgery.  This is not 
ideal for full coverage of the service.  Radiotherapy will be undertaken there and this needs to be funded 
adequately in order to provide a good service. 
 
Over the past year, the number of breast cancers seen at CUH has increased.  Based on data supplied by the 
hospitals. It is estimated that CUH and the South Infirmary have seen between 80 and 100 breast cancers per 
annum.  Recently there has also been increased co-operation and collaboration between the two hospitals.  
Based on the population of the Southern Health Board, as second unit is required.  It is recommended that it 
be based in CUH.  It is recommended that the expertise that exists in Tralee should be utilised in the new 
Breast Unit.  Professionals with an avowed interest from other hospitals should be allowed to participate.  
This will entail making provision for their sessions at the base hospital to be covered while they are 
undertaking sessions at the Breast Unit. 
 
Mid-Western Health Board 
 
The population of the Mid-Western Health Board only justifies one Unit.  A large breast clinic has been 
established in the Limerick Regional Hospital where surgeons from Nenagh, Ennis and St John’s Hospital 
have come together to provide the service.  The Health Board population justifies one unit.  The unit should 
be placed in Limerick Regional Hospital, which has a lot of the activity and ancillary requirements already.  
A breast clinic has been operational in Ennis and the surgeons who run the clinic in Ennis should be 
incorporated into the centre in the Regional Hospital.  If such voluntary involvement arises, there should be 
practical support regarding coverage of their other clinical activities at Ennis Hospital while they are away 
from base conducting breast work in the Unit.  This may mean the appointment of an additional consultant 
surgeon in the region. 
 
Western Health Board 
 
The population of the Health Board justifies one Unit.  The University Hospital in Galway has been 
delivering a service for along time under difficult circumstances.  They are experiencing large demand 
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relative to resources.  The implementation of increased support is an immediate requirement because their 
workload is already present and the need is immediate.  The University Department of Surgery has 
developed a strong clinical service and supplemented it by enterprising clinical research.  There is an 
immediate need for another breast surgeon and support services. 
 
There is not sufficient population to justify a Unit in Castlebar.  The staff at Castlebar Hospital should be 
encouraged to contribute to the Galway Unit if they wish to do so.  As is being proposed for the Mid-
Western Health Board and the Southern Health Board, if professionals from Castlebar wish to become 
involved in the Breast Unit in Galway, provision should be made for their sessions at the base hospital to be 
covered while they are undertaking sessions at the Breast Unit. 
 
North-Eastern Health Board 
 
The population supports only on Unit the North-Eastern Health Board.  Based on the principles already 
discussed in this report, there is no justification for two Units.  The most densely populated area is in the 
southern aspect of the Health Board in Louth and Meath.  This is likely to expand over the coming years.  
Individuals with an expressed interest and expertise in breast services should be incorporated in the Breast 
Unit.  They need to have adequate support in order to cover their regular duties while they are away from 
their own base hospital.  People should be allowed to become involved, provided they meet with the audit 
and CME needs.  Some facilities already exist in Drogheda and this would appear to be an appropriate 
location for the Breast Unit. 
 
North-Western Health Board 
 
The population of this Health Board supports only one unit.  Geographical considerations dictate that an 
innovative approach is required in order to ensure that services are available to patients in acceptable 
settings as far as possible.  In Letterkenny, there is a committed group of people providing a service but they 
do not have a large enough volume of patients with breast cancer.  They will need to link with Altnagelvin 
Hospital in Derry in order to increase their caseload, experience, expertise and formal cross-cover.  If 
collaboration between Derry and Letterkenny occurs, it should be a true liaison.  Scope exists for such a 
liaison to be formalised.  There are strong clinical links between the two hospitals and also between 
Letterkenny and Belfast City Hospital.  These links have been established and are being developed further 
and provide the impetus for a formal arrangement to be established.  Northern Ireland population interest in 
the development of this Unit should be explored with Northern Ireland health authorities.  This sort of 
decision has to be supported at the highest political level so that the highest standards can be maintained and 
for the ease of access and administrative efficiency. 
 
Sligo has insufficient population to justify a unit.  There is currently little infrastructure in Sligo and 
considerable resources would be required in order to set up a Breast Unit there.  However, the only realistic 
proposal would be that, in this particular case, crossing Health Board boundaries could be justified.  If the 
population of Sligo, Leitrim, West Cavan and part of Mayo are incorporated, it is estimated that the 
population would be adequate to provide sufficient volume of patients.  Therefore it is recommended that a 
Breast Unit be established in Sligo serving those areas.  This is an innovative proposal that will require the 
involvement and agreement of the CEO’s and Board of each of the relevant Health Boards.  There will need 
to be agreement that patients cross traditional health board boundaries. 
 
Midland Health Board 
 
The population of the Midland Health Board marginally supports one unit.  There is a small breast service 
currently in Mullingar.  There is no service in Tullamore.  Patients currently travel to Portloasie where a 
long-established unit with considerable clinical expertise and a great deal of ancillary patient- focused and 
oriented support at medical and nursing level has been developed over many years.  Bearing in mind the 
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great majority of women attending the clinic will not have cancer, it is not essential to locate the Breast Unit 
in the designated regional cancer centre.  Because of the delivery of breast services can largely be delivered 
in non-emergency settings, it is unlikely to require high dependency support.  However, there is concern that 
the peripheral location of Portlaoise in the Health Board might militate against achieving the critical mass of 
patients required for the Unit.  There would be a case to be made for locating the Breast Unit in Tullamore 
because of it geographical location in the Health Board and because this would fit in with previous decisions 
made by the Health Board regarding the organisation of oncology and pathology services.  It is essential that 
the available expertise that already exist within the Health Board should be fully utilised in the new Breast 
Unit and professionals with an avowed and continuing interest from the other hospitals should be allowed to 
participate.  This will entail making provision for their sessions at the base hospitals to be covered while 
they are undertaking sessions at the Breast Unit.  Should the decision be to locate the Breast Unit in 
Tullamore then the existing and longstanding expertise of those involved in the Portlaoise unit should 
provide the basis of the service in Tullamore.  This will ensure that a highly valued, quality service will be 
provided to all women in the Midland Health Board region. 
 
Eastern Health Board 
 
In the Dublin region, it is proposed to establish two Breast units on the north side and three on the south side 
of the city.  One of the Units on the north side should be located in the Mater Hospital.  The other Unit, 
based at Beaumont Hospital should involve the participation of interested staff from the James Connolly 
Memorial Hospital in Blanchardstown.  On the south side of the city, separate Breast Units should be 
located in St Vincent’s University Hospital, St James’ Hospital and in Tallaght Hospital. 
 
The Mater Hospital already houses the Eccles Screening Programme and is expected to treat 150 patients 
per year in the prevalent round.  It is appropriate to utilise the expertise at this site for patients in a Breast 
Unit.  It is important to have the Breast Unit in a hospital with a screening unit because follow-up of breast 
cancer detected by screening take place in the Breast Unit.  Many of the staff and most of the infrastructure 
required are already in place. 
 
James Connolly Memorial Hospital and Beaumont Hospital each have breast clinics.  The catchmemt 
population does not support two separate Units.  There are committed professionals who have academic 
links in both hospitals.  They are prepared to work together to develop a Breast Unit on one site but availing 
of the expertise of both hospitals.  This initiative should be supported.  Neither hospital has adequate 
facilities or equipment.  It is proposed that the Unit be sited at Beaumont hospital and should involve 
relevant staff form James Connolly Memorial Hospital.  It is proposed that another consultant surgeon with 
a special interest in breast disease be appointed.  The consultant would have general surgical sessions in 
James Connolly Memorial Hospital and specialised breast session including theatre sessions in Beaumont 
Hospital. 
 
Tallaght is a new hospital and is developing its breast services.  It is located in an area with a very fast 
growing catchment population.  The expanding population base and catchment would indicate that locating 
a unit in Tallaght would be reasonable.  Many of the pathology and radiology requirements are available. 
 
St James’ hospital has a newly established well-audited breast clinic.  Most of the key personnel are 
available, as are the back up facilities.  Its catchment area and the service it provides to the inner city 
population justify a Breast Unit in this hospital. 
 
The first breast clinic in the country was established in St Vincent’s University Hospital and it has been 
providing a symptomatic breast service for twenty years.  The hospital currently treats the largest number of 
breast cancers of any institution in the country.  It is to be one of the screening locations for NBSP and will 
have approximately 150 extra breast cancers from screening.  There is a need for significant investment in 
infrastructure but many of the requirements are in place. 
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Reasons and Evidence for Specialist Breast Unit 
 
Survival Outcomes 
 
There have been many reports in the literature of variations in the standards of care and also variations in 
the outcome of breast cancer patients between and within countries.  Caution is always necessary when 
interpreting such variations.  The survival of a cancer patient depends on the characteristics of the patient, 
on the biology of the disease, and on the quality of the medical services.  Some part of the variation will be 
due to random variation.  Apparent variations may be due to differences in ascertainment of cases and the 
quality and detail of information available in various regions.  Variation in medical care may be due to 
many factors including differences in health care systems, differences in physicians’ practice and styles and 
patient characteristics that may influence how they use the medical services. (77)  Variations in outcome may 
be due to variation in case mix, with sicker patients attending particular hospitals with special expertise.  
Other factors include stage at presentation, treatments administered, and cultural, behavioural and 
environmental factors. 
• Studies have demonstrated important variations in practice among surgeons and among hospitals in the 
management of breast cancer. (48-51, 79,80) 
• Some studies have found better outcome among patients treated by specialists. 
• One Scottish study found that patients with breast cancer have 9% better survival at five years and 8% 
better survival at 10 years when cared for by specialist surgeons. (78) The maximum survival benefit was 
seen in those aged 50 to 64 years and applied across all socio-economic groups. (78) 
• Some studies have found a higher mortality among women who were treated in hospitals that had a low 
volume of breast cancer cases. 
• The increase in mortality can range from 19% in moderate volume hospitals, 30% in low volume 
hospitals and 60% in very low volume hospitals, compared to those who had  their surgery at high 
volume hospitals. (78) 
• While variations in technical surgical practice may not have a large impact on survival, differences in 
the use of systemic adjuvant treatment may influence outcome. (50 , 79,80) 
• Variations in practice, in particular under-use of efficacious treatments represent opportunities to 
improve health and longevity in women with breast cancer. (81) 
• While in Ireland we do not have evidence of poor outcome for women treated at low volume hospitals, 
we do not have the data to determine many aspects of the quality of their care. 
 
Volume 
 
• Radiologists can differ widely in their interpretation of mammograms and their recommendations for 
management. (83)  It is important that radiologists report a sufficient volume of mammograms to attain 
and maintain a high level of performance.  A significant association has been demonstrated between 
recommendations for immediate work-up in cancer cases and the total number of lifetime mammograms 
read.  In one study, radiologists with the highest frequency of recommending immediate work-up in 
cases that proved to be malignant had read more than 15,000 mammograms over their lifetime. (82)  If a 
radiologist only reads 500 mammograms per year it would take 30 years to achieve this level of 
expertise to maximise sensitivity.  Thus, radiologist reporting mammograms need a significant volume 
to achieve optimum cancer detection. 
• It is desirable that a sufficient volume of image guided procedures should be performed to attain high 
pre-operative diagnosis rates. 
• Women managed by individual surgeons treating more than 30 to 50 cases of breast cancer each year 
appear to have better survival, probably because they are more likely to receive adjuvant therapy (79, 50)  
and consultants who treat more patients are also more likely to work in a multidisciplinary team and 
make more use of the full range of therapeutic options for their patients. (50) 
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• The better outcome for patients where there is a high caseload may not be a function of the skill of the 
surgical team but a function of the clinical organisation. (50 , 80) 
• Patients of high volume surgeons are more likely to get adjuvant treatments and are 15% more likely to 
be alive at 5 years compared to patients of low volume surgeons. (51) 
 
Where did the figures for the Breast Unit come from? (1,2 ,3, 4, 5) 
 
Experience in other countries has led to the view that breast disease should be treated in Specialised Breast 
Units with high standards of care (4) through management by surgeons, radiolostist, pathologists, clinical and 
medical oncologists and nurse specialists, each of whom specialises in breast cancer, working as a team and 
providing services from early detection through to care of advanced disease. (3)  Studies abroad have 
demonstrated important variations in practice between surgeons and between hospitals in the management 
of breast cancer.  While variations in technical surgical practice may not have a large impact on survival, 
differences in the use of systemic adjuvant treatment may influence outcome. It is suggested that a viable 
unit would deal with a minimum of 100 breast cancers per year and also deal with the worried well for 
assessment and advice. 
 
The figure of 100 new breast cancer patients per Breast Unit per year is and indicative figure chosen for the 
following reasons: 
• There is evidence of benefit from specialised multidisciplinary care 
• There is evidence of benefit from large volume case load 
• The figure of 100 applies not merely to the surgeons but to the specialist breast team as a whole. 
The figure of 100 is necessary to justify the investment of specialist time and other resources to establish 
and provide ongoing resources for a modern multidisciplinary Breast Unit.  A throughput of 100 cases 
would be expected from a population of 250,000 to 300,000. 
• The level of workload is necessary to sustain the collective expertise of the team. 
• This level of workload is operationally cost-effective for the deployment of a skilled group of people to 
function as a multidisciplinary team. 
• Grouping a number of hospitals together into a ‘‘virtual Breast Unit’’ would not achieve a functioning 
multidisciplinary team. 
• It is not feasible or cost-effective for a group of specialists to meet weekly and invest time and resources 
co-ordinating care if the number of new breast cancer patients falls below two cases per week. 
• A unit seeing 100 cases of breast cancer per year would see at least 1000 new patients with breast 
symptoms annually.  This level of clinical activity (20 new patients per week) would justify the 
provision of a weekly new patient GP referral clinic, which is essential if women are to be seen without 
delay. 
• Professional consensus in the BASO clinical guidelines and other documents of the desirability of such a 
figure. 
• In order to provide the equipment and facilities for an excellent unit resources are required.  It is not 
feasible to provide this level of resources in many hospitals that do not have the volume to utilise them 
to optimal efficiency. 
• In some places a lot of structures are in place and it will be relatively easy to develop the Breast Care 
Unit. 
• There is a common belief that people are not prepared to travel outside their own are for health services.  
However, there is evidence that when people discover that their outcome will be better in terms of 
improved survival, they are prepared to travel. 
 
The multidisciplinary approach 
 
• It is accepted that a multidisciplinary approach to breast cancer affords women the best therapeutic 
options when diagnosed with breast cancer. 
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• Women attending breast clinics have a high level of anxiety.  A multidisciplinary clinic will result in 
most women only having to make a single diagnostic visit to the breast clinic.  There is considerable 
lessening of anxiety if the one diagnostic visit is required. 
• There is a definite cost saving to the health service; multiple visits are demanding on resources. 
• There is also financial saving to the patient and her family.  Most women attending a breast clinic are 
accompanied, frequently by their partner.  This results in absence from work and so reduction in visits 
can result in hidden cost savings to the economy. 
• The cost of establishing high quality multidisciplinary breast clinics is largely offset by the reduction in 
bed occupancy and staffed theatre time. 
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CHAPTER 6 
Structure of a Unit 
 
Introduction 
 
Patients with symptomatic breast disease who present to their GP should be referred directly to a specialist 
breast service.  Direct and early referral will reduce the time to diagnosis, avoid duplication of investigations 
and will ensure that the patient is managed from the outset by multidisciplinary teams with specialist skills.  
The modern management of breast cancer entails triple assessment, which involves the surgeon, pathologist 
and radiologist being in the clinic together.  It reduces the number of unnecessary operations performed for 
benign and malignant breast disease and facilitates rapid diagnosis and better planning of treatment.  The 
proposed structure is based on the guidelines available and the extensive literature on the subject.  The 
Specialist Breast Unit should be based on a population of 250,000 to 300,000 from which it is expected that 
there will be a minimum of 100 new primary breast cancers per annum. 
 
The main components of a Specialist Breast Unit include core personnel, other essential personnel, 
facilities, equipment and organisational elements. 
 
Core Personnel 
 
The core personnel are the people whose presence is considered to be essential for the Breast Team to work 
effectively in delivering a multidisciplinary service.  Some professionals e.g. the radiation oncologist and 
medical oncologist, would not necessarily be based in the hospital where the Breast Unit is located.  
However, they would need to have sessions at the Breast Unit that would enable them to participate fully as 
members of the Breast Team.  Some of the other professionals such as surgeons with an interest and 
expertise in breast disease from other hospitals would also require sessions at the Breast Unit to enable them 
to participate fully as members of the Breast Team. 
 
The core personnel are as follows: 
• Lead Clinician 
• Breast Surgeons (lead surgeon normally 6 sessions, each other surgeon 3 sessions each) 
• Breast Radiologist (4 sessions) 
• Breast Pathologist (4 sessions) 
• Breast Care Nurse (2 WTE per 100 cancers) 
• Clinic Nurses (1WTE).  They will probably be shared with the general outpatient department. 
• Medical Oncologist 
• Radiation Oncologist 
• Radiographers (2 WTE) 
• One Administrative Officer (Grade VI or VII) 
• Two Clerical Officers (Grade IV or V).  Depending on the workload, three may be required. 
• One Data Manager. 
 
Other essential personnel 
 
This includes other staff that are essential for the delivery of a high quality diagnostic and therapeutic 
service.  Women must have access to the expertise of these professionals.  A liaison system, which involves 
good communication and early involvement in woman’s care, is necessary to ensure that the relevant 
professionals are brought in at the appropriate time. 
• Plastic surgeon 
• Clinical psychologist or psychiatrist 
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• Palliative care specialists 
• Physiotherapist/occupational therapist 
• Social worker 
• Clinical Geneticist 
• Pharmacist 
 
The breast care nurse provides a valuable service and the supportive care and skills in counselling of 
specialist nurses are most important.  A specific training programme for such nurse specialists is a 
requirement.  One whole time equivalent breast care nurse is required per 50 new cases of breast cancer per 
year.  This implies that three breast care nurses are needed for Units treating 150 patients and four nurses 
required for Units treating 200 patients.  One of the key functions of the breast care nurse is to provide 
support and counselling to women who attend at the Breast Unit. 
 
The area of support services such as counselling and social work needs to be examined further.  The survey 
of ‘‘women’s views and perceptions of the symptomatic breast services’’ undertaken by the Women’s 
Health Council which will be submitted to the National Cancer Forum on completion, will provide 
information regarding what women wish to see provided in this area. (8)  Any developments in the provision 
of support services for patients with cancer should be guided by the national review that was undertaken of 
support services for patients with cancer. (10) 
 
Facilities 
 
Care for women with breast cancer should be provided in a friendly, comfortable environment with private 
areas for consultation and counselling.  Consideration should be given to the need for changing facilities and 
the proximity of the various diagnostic and consulting areas.  Necessary accommodation will include: 
• Reception area 
• Waiting room 
• Outpatient clinic accommodation which is close to the imaging area 
• Radiology, including mammography, ultrasound and imaging guidance for localisation procedures 
• Pathology room for storage of cytology specimens and a microscope 
• Nurse counselling area 
• Inpatient beds 
• Operating time 
It is important that there is adequate space for the clinic.  In some centres the accommodation is already 
available.  The clinical rooms should be in close proximity to the breast imaging area (mammography and 
breast ultrasound).  This is important as women will change for clinical examination and ideally should be 
able to proceed to imaging without dressing and undressing.  There should be the facility for a pathology 
room for storing cytology specimens and a microscope.  The nurse counselling area should be placed in 
close proximity to the clinic so that distressed women do not have to walk far. 
 
The requirements for beds and theatre are unlikely to increase.  High pre-operative diagnosis will result in 
fewer requirements for surgical beds and theatre time.  Some local reorganisation may be required to ensure 
admission and treatment within acceptable time scales. 
 
Equipment 
 
In order to provide high quality multidisciplinary care, a basic level of equipment provision is necessary.  
This includes: 
• Stereotactic mammography machine – approximately £130,000 
• Basic mammography unit approximately £50,000 
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• Processing equipment approximately £50,000 
• Ultrasound machine approximately £50,000 
• IT support and database 
• Microscope for Pathologists 
 
Organisation 
 
The planning of care involves all members of the Breast Care Team, who must communicate with all other 
professionals who are involved in the woman’s care.  At any particular time in her care there should be a 
principal clinician with whom she relates.  In the early stages this will be the surgical oncologist, during 
adjuvant therapy it will be the medical oncologist and the radiation oncologist, and at a late stage it may be 
the palliative care physician.  There should also be a Lead Clinician for the Breast Unit.  The Lead Clinician 
should generally be the surgeon because 
a) the majority of patients presenting to the Breast Unit do not have cancer and do not require the 
services of a medical oncologist or radiotherapist, but do need the surgical specialist for clinical 
assessment and reassurance 
b) it is the surgeon who is the first point of medical specialist contact with the patient in the hospital 
setting 
c) it is the surgeon who, on diagnosis, discusses and undertakes the primary treatment for patients 
who have cancer in the great majority of cases. 
The Lead Clinician must have the skills to lead the Unit and promote the development of audit, protocols 
and quality assurance measures.  Important elements of the organisation of the Unit are listed below. 
• The range of clinics will include: new patient clinic, result clinic, follow up (general follow up clinic, 
combined clinic for advanced/metastatic disease with medical onlcology  and radiation oncology, clinic 
for women with low risk of recurrence), family history clinic, mastalgia clinic. 
• Each team should hold weekly multidisciplinary meeting to discuss the clinical management of patients.  
All relevant members of the Breast Care Team should attend the meetings.  All patients should be 
discussed: new cases pre-operatively and post-operatively; patients with recurrent or advanced disease; 
cases which present difficulties in management; other cases where appropriate. 
• During the meeting the team should agree and document the treatment plan for each patient, agree 
further investigation, agree which patient should be offered entry to approved clinical trials and refer 
patients for treatment such as oncology where necessary. 
• A record of meetings should be documented. 
• Adequate and clear communication between all those involved in the woman’s care is important. 
• Adequately funded quality assurance is necessary. 
• Audit through collection of data using a specially developed proforma.  Information is co-ordinated by a 
data manager and formally presented and evaluated regularly at a Breast Unit and at national level. 
• All members of the multidisciplinary team should have the opportunity of specialist training. 
• Development of national guidelines and protocols that are agreed nationally. 
• Research is fundamental to a high quality Breast Unit and Units should be encouraged to  
a) develop clinical research activity 
b) liaise with existing academic centres where basic research is conducted 
c) become involved in clinical trials 
 
 
Clinical trials 
 
Clinical trials are the basis for the development of the knowledge, which leads to the best treatment methods 
for breast cancer. 
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• Breast Units should support clinical research and should participate in a programme of multi-centre 
clinical research and clinical trials aimed at improving the treatment of breast cancer. (3) 
• While it is the right of any individual patient to decide whether she wishes to take part in a clinical trial, 
participation in clinical trials must be encouraged. 
• Clinical trials need to become more acceptable to the public as well as to the medical community for 
much more to be achieved that increases knowledge about breast cancer and its management. (14) 
• This can be achieved through involving patients more fully in the design and conduct of the trials. 
• Excessive extrapolation of results from existing clinical trials are reliance upon indirect evidence might 
be detrimental to the development and validation of effective treatments. (14) 
• Those involved in trials should co-ordinate their efforts to avoid unnecessary duplication and to provide 
added value through pooling data. (2) 
 
Quality Assurance Office 
 
A centralised Quality Assurance Office should be established and staffed appropriately with a data 
collection and evaluation manager supported by clerical staff.  It should 
• collect data from the regional Breast Units, 
• co-ordinate and organise the annual audit/outcome meetings and 
• produce a National Annual Report. 
• be located in the Reference Unit 
 
Reference Units 
 
A Reference Unit should be established to provide support and advice to Breast Units throughout the 
country.  This Reference Unit could provide second opinions if appropriate for more complex or unusual 
cases.  This would be in the form of advice and where possible returning the patient to the referring Breast 
Unit for appropriate treatment.  The Reference Unit should be encouraged to establish a teaching and 
training/continuing education programme.  This should be multidisciplinary and involve both formal and 
informal training facilities.  The Reference Unit should facilitate the other Units with research and other 
academic activity. 
 
The main function of the Reference Unit would be to 
• co-ordinate all the Units 
• act as a facilitator and advisor to other Units, particularly in unusual or complex cases, 
• promote research activity among Units and co-ordinate clinical research 
• be responsible for additional specialist training 
• house the Quality Assurance Office 
 
Communication 
 
The diagnosis and treatment of breast cancer involves many professionals within the Breast Unit, across 
hospital departments, between hospitals, between the hospital and the GP and with voluntary organisations.  
Difficulties with communication will militate against high quality care and may also promote complaints 
and litigation.  The CAWAC survey found that although 94% of women with breast cancer were satisfied 
with the overall care they received, only 62% were satisfied with the level of communication between their 
GP and the hospital and only 67% were satisfies with the co-ordination of their treatment across hospital 
departments. (19) It is recommended that the role of cancer co-ordinators be explored to help facilitate 
communication and co-ordination of cancer services.  This is important not only to aid communication with 
GPs but also to help link women with support systems and services located in the community. 
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When the new Breast Units are established, all professionals especially GPs should be informed of the new 
arrangements.  They should understand how to access the appropriate service for their patients.  Adequate 
and clear communication between all those involved in the woman’s carE is important.  Administrative 
structures are necessary to ensure: 
• Communications with GP, family, other team members 
• Rapid access for appointments and efficient processing of data 
• Accuracy of data 
• Adequate recording of all relevant clinical, radiology, pathology, chemotherapy, radiotherapy, 
biological and other data 
• Consistency of records within elements of the Unit and among the Units 
 
Family History Clinics 
 
A number of dedicated family history clinics should be established.  The Reference Unit would be an 
appropriate location for such a clinic.  When a woman has a relative risk of breast cancer that is three times 
that of the general population, referral to a Specialist Breast Unit is advisable.  Women with less than three 
times increased risk probably do not require extra surveillance.  There are charts available that aid in the 
assessment of increased risk for women with relatives with breast cancer.  They should be kept under 
surveillance with regular examination and/or mammography at an appropriate age.  These data should be 
collected and correlated nationally.  There are approximately 3000 to 4000 such women per million 
population.  These women should attend family history clinics based at breast clinics. Woman with ten 
times increased risk should be referred to a dedicated genetic family history clinic. There are approximately 
10-15 such families per million population (based on UK data).  These women will require counselling and 
perhaps genetic testing. 
 
The role of family history in the aetiology of cancer is an important area that is not confined to breast 
cancer.  It is an issue that requires detailed examination, with the view to providing centralised genetic 
services for all cancers.  It was not the remit of the sub-group to examine this subject in detail.  The 
recommendations apply only to the immediate needs for women with breast cancer and are not intended to 
go beyond that.  The issue of inherited predisposition to cancer in general needs to be fully evaluated by 
experts in the field. 
 
Financial Implications of Establishing Breast Units 
 
There is significant cost associated with the establishment of a unit.  There will however be savings due to 
the increased efficiency particularly if 80% of women make only one diagnostic visit.  The review 
appointments utilise valuable clinic time and there is a significant potential cost saving to the patient and the 
economy due to reduction in clinic visits. 
 
The sub-group did not consider it appropriate to attempt to provide detailed costing for the Breast Units.  
Some locations have some of the necessary facilities and staff in place already. Others would need a large 
injection of resources in order to establish a Breast Unit.  A detailed needs assessment will be required for 
each proposed centre by the Department of Health & Children and the Health Boards to determine the exact 
requirements in each location based on what is already available. 
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CHAPTER 7 
Quality Assurance Structure 
 
Introduction 
 
It is important that quality assurance structures are put in place to ensure that women receive the highest 
standard of care.  Clinicians involved in the service must be prepared to perform regular audit.  Audit is the 
systematic and critical analysis of the quality of care including the procedures for diagnosis and treatment, 
the use of resources and the resulting outcome and quality of life of the patient.  It is an essential part of 
clinical care.  This is vital not only to ensure standard but also to enable clinicians to monitor their own 
performance.  Most clinicians work to very high standards but work in the field of breast cancer diagnosis 
and treatment has become increasingly difficult due to medico-legal challenges.  Participation in quality 
assurance is usually reassuring to clinicians and enables them to realise that they are performing similarly to 
their other colleagues in the field in other Units.  Quality assurance must be the sharing of experience and 
must not be threatening to the individual professional.  There will a requirement for each sub-speciality 
group to perform their own quality assurance.  It will be important that this is done confidentially within the 
relevant professional group.  Inter-disciplinary audit will be required to monitor the performance of the Unit 
as a whole. 
• All members of the Breast care team should participate in the audit of the structure, process and 
outcomes relating to the breast service. 
• Team members should participate in relevant sub-specialist regional meetings. 
• Regional forums should be established among all professional groups to enable then to share 
experiences, promote audit and continuing professional development. 
• A range of guidelines should be developed nationally to promote a consistent evidence-based approach 
to the management of breast disease. 
• Close liaison between the pathology laboratory and the National Cancer Registry is necessary. 
• A standard set of data is necessary using the same diagnostic criteria. 
• People appointed need to have special interest and specific training in breast disease and undertake to 
attend CME.  This must be funded. 
• The monitoring of CME is based on the acquisition of credits granted. 
• Regular meetings of all Units are necessary. 
• External visits to each Unit. 
 
There are a number of components to a Quality Assurance programme: 
• Training, both initial and continuing medical education 
• Unit audit 
• Subspecialty Audit (National) 
• Multidisciplinary Audit (National) 
• Guidelines 
 
Training 
 
All members of the multidisciplinary team should have the opportunity of specialist training.  Many people 
already working in the field will have been appointed prior to the establishment of formal training 
programmes.  Some clinicians would value the opportunity of a refresher-training course.  This facility 
should be available if required.  Future Consultant appointments in surgery, radiology and pathology with a 
formal sub-speciality interest should have acceptable sub-speciality training.  There should be funding 
available for staff to attend continuing medical education.  This should be mandatory as agreed by each sub-
speciality group.  A suggested guide for training and recruitment of consultant breast surgeons is shown in 
Appendix 4. 
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Unit Audit 
 
Breast Units must assess the care they provide (care process and outcome) and there should be an 
environment of critical self-appraisal.  Audit should assess the quality of care using objective criteria.  The 
Units should keep accurate records of diagnostic, staging, treatment and follow-up data.  There should be a 
nationally agreed minimum database for all Breast Units.  A Data Manager should collect relevant data.  
Each Unit should meet regularly (probably 6 monthly) to formally present and evaluate the Unit statistics.  
The lead clinician in the Unit should be responsible for and have the ownership of the Unit data.  The Unit 
will be required to have close links with the National Cancer Registry. 
 
Sub-Speciality Audit (National) 
 
Breast cancer is diagnosed and treated by a number of sub-speciality groups.  There are performance review 
indicators that are specific to each sub-speciality group.  It is important that these sub-speciality groups 
should meet regularly to provide professional support and formal audit.  The sub-speciality groups should 
establish professional standards and guidelines.  Regular national sub-speciality meetings will benefit 
individuals working in the field and will help raise and maintain standards.  Each group should elect a 
chairperson for an agreed term of office.  The chairperson would collect relevant data on each sub-
speciality.  This chairperson would represent the group on a national executive multidisciplinary committee.  
Sub-speciality audit must be the result of equal participation of all individuals in the group.  Confidentiality 
should be respected but if there is a potentially serious deviation from the standard the chairperson should 
be enabled to take remedial action. 
 
Multidisciplinary Audit (National) 
 
It is important that national data are collected and analysed.  An executive multidisciplinary committee 
should be established with membership form each sub-speciality group.  An annual meeting of professionals 
involved in the diagnosis and treatment of breast diseases should review key performance and outcome 
indicators i.e. clinic wait time, percentage patients diagnosed at single visit, bed wait times, benign biopsy 
rates, pre-operative cancer detection rates, percentage tumours less than 15mm undergoing conservation 
surgery, re-excision rates, lymph node status, etc.  Audit should be an integral part of the service just as in 
breast screening.  The annual meeting will result in the sharing of information and should help develop a 
collegiate atmosphere amongst those delivering the service.  It would be appropriate to have an academic 
session at the time of the presentation of the annual report.  An interested speaker would be of considerable 
value. 
 
A national Quality Assurance Office should be developed.  The national Quality Assurance Office should be 
centrally funded and could be located in the Reference Unit.  It should be staffed by a data manager with 
clerical support and should receive regular downloads from the Units.  The chairperson of the 
multidisciplinary committee should with the support of the Quality Assurance Office produce an annual 
report with evaluation of key performance indicators.  This report would include wait times for initial 
diagnostic visit, number of diagnostic visits, wait time for diagnostic and therapeutic surgery.  Information 
on adjuvant treatment should be collected including details of radiotherapy and chemotherapy regimes. 
 
An Irish Breast Group should be established to facilitate quality assurance, development of protocols and 
the sharing of information and expertise.  A sub-group should be appointed and designated to promote and 
co-ordinate research into the field of breast cancer. 
 
 
National Guidelines 
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Each sub-speciality group should issue guidelines on patient management.  These guidelines should include 
acceptable professional standards.  These guidelines should be agreed nationally, implemented locally and 
reviewed nationally.  Only clinicians who agree to practice guidelines and perform audit should provide the 
service. 
Written guidelines and protocols should be available for each component of care; GP, surgeon, radiologist, 
pathologist, medical oncologist, radiation oncologist, breast care nurse, physicist, management, and 
secretarial staff.  With the introduction of guidelines and protocols there is likely to be an increase in the use 
of systemic adjuvant therapy in early breast cancer.  The additional costs that result are likely to be balanced 
by a reduction in treatment costs for recurrence and for advanced disease.  Guidelines should be continually 
evolving.  Effective implementation is essential. 
 
Reasons why Quality Assurance is needed 
 
Knowledge and skills relevant to clinical practice must be kept up to date throughout working life.  Regular 
audit and quality assurance raises standards.  Departments must assess the care they provide (both care 
processes and outcome).  There should be an environment of critical self-appraisal. 
• The quality of care should be evaluated using objective criteria. 
• The diagnosis and treatment of breast disease has many key processed that can be subjected to objective 
standard analysis.  It is imperative that each individual part of the process is audited but the overall 
outcome is important. 
• It is important that the clinician and radiologist locate the lesion accurately and that the pathologist can 
make a definite diagnosis.  All aspects of the process must be monitored. 
• Performance in mammography is directly related to expertise.  There is evidence of improvement in 
radiologists’ interpretation after dedicated teaching courses. (89)  There is also evidence of improvement 
in small cancer detection when the number of radiologists involved in reporting is restricted. (90) 
• Because of the demanding nature of the mammographic technique, rigorous attention to the use of 
appropriate equipment and performance of quality assurance by the radiologist, the radiographer and 
medical physicist is required. 
• Quality assurance of physical and technical aspects of mammography must include equipment 
specification, acceptance testing and routine quality control.  The importance of high quality standards 
in mammography imagining has been recognised by many organisations and countries world wide most 
notably the EU (91, 92,93,94) and the United States which has legislated through the Mammography Quality 
Standards Act. 
• The image quality must be stable with respect to information content an optical density and the radiation 
dose to the breast must be as low as reasonably achievable for the diagnostic information required.  The 
demands on image quality hod for every mammogram produced and the quality assurance program must 
ensure that high quality images are achieved consistently. 
• The need for quality assurance has been recognised by the Royal Colleges and guidelines have been 
developed. 
• The importance of reviewing guidelines has been demonstrated by the UK NHS BSP Pritchard 
Guidelines, which were issued prior to the establishment of the Programme.  These have been reissued 
and the standards raised twice over the last 10 years. 
• It is important that the Republic of Ireland collects data in the future that will allow comparison with 
survival patterns stage by stage in other countries.  The collection and analysis of data and performance 
will lead to a uniformly high quality assurance service for women attending clinics with breast 
symptoms throughout the country. 
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Appendix 1 
 
Membership of Sub-Group on Symptomatic Breast Cancer Services 
 
Prof James Fennelly*, Chairperson National Cancer Forum, 21 Alma Road, Monkstown, CO Dublin. 
 
Dr Jane Buttimer, Director, National Breast Screening Programme, Corrigan House, Fenian Street, Dublin 2 
 
Ms Sioghan Carroll, Breast Care Nurse, c/o Prof Paul Redmond, Cork University Hospital, Cork. 
 
Prof Eugene Connolly*, Consultant Pathologist, University College Hospital  Galway. 
 
Prof Peter Daly*, Consultant Medical Oncologist, St James’s Hospital, James’s St, Dublin 8. 
 
Prof Donal Hollywood*, Regional Director of Cancer Services, Midland Health Board, and Consultant 
Radiotherapist, St Luke’s Hospital, Highfiels Road, Rahgar, Dublin 6. 
 
Mr John Kelly, Consultant Surgeon, South Infirmary-Victoria Hospital, Old Blackrock Road, Cork. 
 
Mr Michael Lyons*, Principal Officer, Secondary Care Division, Department of Health and Children, 
Hawkins House, Dublin 2. 
 
Ms Geraldine Luddy, Chief Executive, Womens Health Council, Irish Life Centre, Abbey St., Dublin 1 
 
Mr Peter Naughton, Consultant Surgeon, Portlaoise General Hospital, Portlaoise, Co. Laois. 
 
Prof Niall O’Higgins*, Prof of Surgery, University College Dublin (St Vincent’s University Hospital, Elm 
Park, Dublin 2). 
 
Dr Bernadette O’Keefe*, Deputy Chief Medical Officer, Department of Health and Children, Hawkins 
House, Dublin 2. 
 
Dr Orlaith O’Reilly*, Director of Public Health, South Eastern Health Board, Lacken, Dublin Road, 
Kilkenny. 
 
Mr John Reynolds, Regional Director of Cancer Services and Consultant Surgeon, Waterford Regional 
Hospital, Ardkeen, Waterford. 
 
Dr Greg Kelly*, General Practitioner, Knockrae, Castlerea, Co Roscommon. 
 
* = Member of National Cancer Forum 
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Appendix 2 
 
List of Hospitals Visited 
 
Health Board Regional Director Hospital Visited * 
SEHB Mr. Gordon Watson Waterford Regional Hospital 
SHB Prof. W.O. Kirwan Cork University Hospital 
  South Infirmary, Cork 
  Tralee General Hospital 
WHB Mr. Oliver McAnena University Hospital Galway 
  Castlebar General Hospital 
MWHB Dr. Tom Peirce Limmerick Regional Hospital 
NEHB Mr. Finbar Lennon Our Lady of Loourdes Hospital, Dorgheda 
 Dr. Deborah Condell Cavan/Monaghan Hospital, Cavan 
NWHB Mr. Kevin Moran Sligo General Hospital 
  Beaumont Hospital 
EHB Prof. David Bouchier-Hayes Mater Misericordiae Hospital 
  St Vincent’s University Hospital 
 Mr. John Hyland Meath, Adelaide, NCH, Tallaght 
 Mr. John Reynolds St James’ Hospital 
  Mullingar General Hospital 
MHB Prof. Donal Hollywood Tullamore General Hospital 
  Portlaoise General Hospital 
* Representation form other relevant hospitals in the Health Board was arranged througj the Regional 
Directors of Cancer Services. 
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Appendix 4 
 
Training of General Surgeon with Special Interest in Breast Disease 
 
Programme 1 
 
The level of training which a general surgeon with sub-speciality interest will be expected to have achieved 
by the end of Higher Surgical Training 
 
• General Surgeon with special interest in breast disease should spend one year in higher training working 
50% of the time for a consultant with special interest in breast disease in a Breast Unit. 
• Should spend additional 6 months full-time in a Reference Breast Unit. 
• Should spend one month in a Medical Oncology service and one month in a Radiotherapy Unit. 
• Should spend a period of one month in a specialist Palliative Care Unit. 
 
Programme 2 
 
That level of subspeciality training that will be required of a consultant who might practice almost 
exclusively in breast diseases. 
• One year of training spending 50% of time with a consultant with a special interest in breast disease in a 
Breast Unit. 
• One year of training in a Reference Breast Unit. 
• Flexible year of research related to breast disease. 
• At least one month each in Medical Oncology and Radiotherapy Unit. 
• Time spent in Pallitative Care also desirable. 
• Should spend a period of one month in a specialist Palliative Care Unit. 
 
Requirements for a Post Advertised for Consultant General Surgeon with a Special Interest in Breast 
Diseases 
 
• Dedicated Breast Unit with full secretarial support. 
• Two Breast Care Nurses 
• Expert on-site breast radiology/ultrasound 
• Expert on-site breast cytology/histopathology 
• Radiation Oncologist and Medical Oncologist with special interest in breast cancer on-site or visiting at 
least twice a week 
• Specialist palliative care service on site or attending the Unit at least twice a week 
• Adequate access to breast reconstruction 
• Counselling and psychological support systems in place 
• Computer database with adequate secretarial and data management input 
• Adequate inpatient beds and operating time to meet the clinical guidelines 
• External Assessor should be a surgeon who specialises in breast disease 
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